Fusion protein comprising anti-TIGIT antibody and TGF-βR, and pharmaceutical composition and use thereof
Patent Information
- Application Number
- JP2024509425
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-08-20
- Filing Date
- 2022-08-22
- Publication Date
- 2024-11-12
AI Technical Summary
【0073】 本発明の有益な効果 本発明は以下の技術的効果(1)~(9)のいずれか1つ以上を達成する。 (1)本発明の融合タンパク質(例えばTF01又はTF02)が、TIGITの阻害及びTGF-β濃度の減少を同時に可能にする。 (2)本発明の融合タンパク質(例えばTF01又はTF02)が、TIGITに極めて特異的に結合することができ、TIGITのCD155への結合を極めて効果的にブロックすることができ、生物におけるTIGITの免疫抑制を特異的に緩和することができる。 (3)本発明の融合タンパク質(例えばTF01又はTF02)が、TGF-βに極めて特異的に結合することができ、TGF-βのTGF-β受容体への結合を極めて効果的にブロックすることができ、生物におけるTGF-βによる免疫抑制を特異的に緩和し、免疫応答を活性化することができる。 (4)本発明の融合タンパク質が抗腫瘍薬の調製に対して高いポテンシャルを有する。 (5)本発明の融合タンパク質の第1タンパク質機能領域及び第2タンパク質機能領域が相乗効果を有し、その効果が、いずれかのタンパク質機能領域を単独で使用した融合タンパク質と比べて優れている。 (6)本発明の融合タンパク質、特にTF01が、Fc受容体FcγRI、FcγRIIb、FcγRIIa_H131、及び/もしくはFcγRIIa_R131、FcγRIIIa_V158、及び/もしくはFcγRIIIa_F158に対する結合活性を完全に取り除いたものであり、且つ、ADCC活性又はADCP活性を取り除いたものである。 (7)本発明の融合タンパク質、特にTF01が、補体C1qに対する結合活性を完全に取り除いたものであり、且つ、CDC活性を完全に取り除いたものである。 (8)本発明の融合タンパク質、特にTF01及びTF02の両者が、TIGITによって誘導された免疫細胞の免疫抑制を効果的にブロックすることができ、且つ、細胞のIL-2分泌を誘導することができる。 (9)本発明の融合タンパク質、特にTF01が、TGF-βによって誘導された免疫細胞の免疫抑制を効果的にブロックすることができ、且つ、細胞のINF-γ分泌を誘導することができる。
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] The present invention belongs to the field of biomedicine and relates to a fusion protein comprising an anti-TIGIT antibody and TGF-βR, as well as its pharmaceutical composition and use. [Background technology]
[0002] TIGIT (T cell Ig and ITIM domain; also known as WUCAM, Vstm3, or VSIG9) is a member of the poliovirus receptor (PVR) / nectin family. TIGIT consists of an extracellular immunoglobulin variable region (IgV) domain, a type I transmembrane domain, and an intracellular domain with classical immunoreceptor tyrosine-dependent inhibitory motifs (ITIM) and immunoglobulin tail tyrosine (ITT) motifs. TIGIT is highly expressed in lymphocytes, particularly in effector and regulatory CD4+ T cells (Treg cells), follicular helper CD4+ T cells, effector CD8+ T cells, and natural killer (NK) cells (Yu X, Harden K, Gonzalez LC, et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.[J]. Nature immunology, 2009, 10(1):48).
[0003] CD155 (also known as PVR, Necl5, or Tage4), CD112 (also known as PVRL2 / nectin2), and CD113 (also known as PVRL3) are ligands that TIGIT binds (Martinet L, Smyth M J., Balancing natural killer cell activation through paired receptors.[J]. Nature Reviews Immunology, 2015, 15(4):243-254), and among these, CD155 is a high-affinity ligand for TIGIT. In NK cells, binding of TIGIT to the ligands CD155 and CD112 inhibits the killing effect of NK cells against cells with high CD155 and CD112 expression (Stanietsky N, Simic H, Arapovic J, et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.[J]. Proceedings of the National Academy of Sciences, 2009, 106(42):17858-17863). It has been reported that the killing effect of CD8+ T cells is enhanced when PD-1 and TIGIT are simultaneously blocked (Johnston RJ, Comps-Agrar L, Hackney J, et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function.[J]. Cancer cell, 2014, 26(6):923-937). Recent studies have demonstrated that TIGIT, as an immune checkpoint for NK cells, can lead to the exhaustion of NK cells during tumor growth.It has also been shown that anti-TIGIT monoclonal antibodies can reverse NK cell exhaustion and can be used for immunotherapy of various tumors, including non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B cell lymphoma, and plasmacytoma (Zhang Q, Bi J, Zheng X, et al., Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.[J]. Nature immunology, 2018, 19(7):723-732).
[0004] Furthermore, it was reported that TIGIT blockers alone or in combination with PD-1 and CD96 blockers could significantly reduce the growth of B16 melanoma in wild-type and CD155- / - mouse models (Li XY, Das I, Lepletier A, et al., CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest, 2018, 128:2613-25). CD112R blockers alone or in combination with TIGIT and / or PD-1 blockers could enhance the cytokine production ability of TILs in ovarian, endometrial, and lung cancers (Whelan S, Ophir E, Kotturi MF, et al., PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell function. Cancer Immunol Res, 2019, 7:257-68).
[0005] The transforming growth factor-β (TGF-β) superfamily is a functionally diverse class of cytokines that can be further divided into subfamilies, including TGF-β, activins, inhibins, growth differentiation factors (GDFs), glial cell line-derived neurotrophic factors (GDNFs), Nodal, Lefty, and anti-Mullerian hormones (Table A). The TGF-β subfamily includes three proteins, TGF-β1, TGF-β2, and TGF-β3, respectively, with TGF-β1 being the most highly expressed subtype. Upon binding to their receptors, TGF-β1, TGF-β2, and TGF-β3 mediate diverse biological responses through Smad and non-Smad signaling pathways. Examples include epithelial-mesenchymal transition (EMT), pro-tissue fibrosis, pro-angiogenesis, tumor-promoting immune evasion, and cancer inhibition and promotion dual action (J Massague. TGFbeta in Cancer.[J]. Cell, 2008, 134(2):215-230).
[0006] TGF-β receptors (TGF-βR) are widely distributed on the surface of normal and tumor cells in humans and include three receptor superfamilies. Among these, the classical TGF-β receptor family type I includes ALK1-7, and TGF-βRI (also called TβRI), also known as ALK5; the classical TGF-β receptor family type II includes TGF-βRII (also written as TβRII), ActRII, ActRIIB, AMHRII, and BMPRII; the TGF-β receptor superfamily type III includes betaglycan (also known as TGF-βRIII) and endoglin; TGF-βRI, TGF-βRII, and TGF-βRIII can bind to TGF-β1, TGF-β2, and TGF-β3, respectively (Pawlak John B, Blobe Gerard C, TGF-β superfamily co-receptors in cancer. DevDyn, 2021). The TGF-β family and receptors are shown in Table A (summary of review based on Carl-Henrik Heldin1 and Aristidis Moustakas. Cold Spring Harb Perspect Biol. 2016). TGF-βRI and TGF-βRII are serine / threonine protein kinase receptors. As a key molecule in signal transduction in the TGF-β signaling pathway, TGF-βRII can bind to TGF-β with high affinity to form a heterotetrameric receptor with TGF-βRI dimers, which is then phosphorylated by autophosphorylation to activate TGF-βRI. Activated TGF-βRI phosphorylates downstream Smad pathway-related proteins, regulates the transcription and translation of downstream target genes, and further causes biological responses associated with diseases. Compared with TGF-βRI and TGF-βRII, TGF-βRIII has a weaker affinity for TGF-β and does not have an intracellular segment. Therefore, it is not connected to the downstream signaling pathway. The function of TGF-βRIII is to capture and present TGF-β to TGF-βRII.Other TGF-β receptors can also bind to TGF-β (Sang Xiaohong et al., Advances in researches on small molecule inhibitors targeting TGF-β and receptors.[J]. Journal of Pharmacy, 2019(9)). [Table 1-1] [Table 1-2]
[0007] During tumor progression, tumor cells, mesenchymal fibroblasts, and other cells secrete large amounts of TGF-β into the tumor microenvironment (TME) to mediate immune suppression. TGF-β inhibits naive T cells from differentiating into Th1, which mediates antitumor activity, and TGF-βRII-deficient T cells have enhanced Th1 responses (Eduard, Batlle, Joan, et al., Transforming Growth Factor-β Signaling in Immunity and Cancer.[J]. Immunity, 2019). Granzyme A, granzyme B, perforin, gamma-interferon (IFN-γ), and FasL of effector T cells with tumor-killing activity are downregulated under the activity of TGF-β, resulting in immune evasion of tumor cells. Tregs are key cells mediating tumor immune suppression by the tumor microenvironment (TME) and can inhibit the function of effector T cells with tumor-killing activity. TGF-β produced by tumor cells generates a large number of Tregs in the TME, enhancing tolerance to tumor antigens and promoting the generation of tumor immune evasion (Chen Dan, Ran Yan. Advance in researches on the regulation and control of tumor cells and tumor-associated immune cells by TGF-β.[J]. Modern Medicine & Health, 2020, 36(09):1354-1358). Investigational antibody drugs targeting TGF-β molecules, currently in clinical trials, are indicated for melanoma, renal cell carcinoma, breast cancer, cervical cancer, advanced non-small cell lung cancer, prostate cancer, pancreatic ductal adenocarcinoma, advanced solid tumors, and metastatic solid tumors.
[0008] Fc receptors belong to the immunoglobulin family and are expressed on the surface of certain immune cells, where they mediate immune responses by recognizing the Fc region of antibodies. When the Fab region recognizes an antigen, the Fc region of the antibody binds to the Fc receptor on the immune cell (e.g., killer cell) and initiates the immune cell's response functions, such as phagocytosis and ADCC.
[0009] Fc receptors are mainly classified into three types, FcγR, FcαR, and FcεR, according to the type of antibody that the Fc receptor recognizes and the type of cell that expresses it. FcγR can be further classified into four subtypes, FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), and FcRn (neonatal Fc receptor). Of these, FcγRI, FcγRII, and FcγRIII are closely related to ADCC effects. FcγRIII is the most predominant molecule that mediates ADCC, and there are two highly homologous subtypes, FcγRIIIa and FcγRIIIb, in different cell types. The FcγRIIIa population has two subtypes that are distinguished by a single nucleotide polymorphism (SNP) site: high affinity FcγRIIIa_V158 and low affinity FcγRIIIa_F158. FcγRI has high affinity for the Fc region of IgG and is involved in the ADCC process. FcγRII includes three subtypes, FcγRIIa, FcγRIIb, and FcγRIIc (also called CD32a, CD32b, and CD32c, respectively), of which FcγRIIa has ADCC activity. FcγRIIa has two subtypes in humans, FcγRIIa_H131 and FcγRIIa_R131, due to a single nucleotide mutation. FcγRIIb is an inhibitory receptor and a typical inhibitory FcγR that inhibits the nearby ITAM pathway. For example, after binding of an immune complex to the BCR, the Fc fragment binds to FcγRIIb on the same cell, negatively regulating B cell activation and reducing antibody and cytokine secretion (Hogarth PM, Pietersz GA., 2012, NATURE REVIEWS DRUG DISCOVERY, 11(4):311-331).
[0010] There is currently a need to develop drugs that inhibit both the TIGIT and TGF-β signaling pathways. Summary of the Invention
[0011] Through intensive research and creative efforts, the present inventors have constructed a fusion protein comprising an anti-TIGIT antibody and TGF-βR, and have surprisingly found that the fusion protein can effectively bind to TIGIT and TGF-β simultaneously, and has potential in the preparation of antitumor drugs. The present invention is described in detail below.
[0012] One aspect of the present invention is The first protein functional domain that targets TIGIT; and a second protein functional domain with TGF-β binding activity; A fusion protein comprising: the first protein functional domain is an anti-TIGIT antibody or an antigen-binding fragment thereof; the heavy chain variable region of the anti-TIGIT antibody comprises HCDR1 to HCDR3 having the amino acid sequences of SEQ ID NOs: 3 to 5, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences of SEQ ID NOs: 8 to 10, respectively; Concerning fusion proteins.
[0013] In some embodiments of the present invention, the heavy chain variable region of the anti-TIGIT antibody comprises an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; the light chain variable region of the anti-TIGIT antibody comprises an amino acid sequence selected from SEQ ID NO:6, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:25; Fusion proteins are provided.
[0014] In some embodiments of the present invention, the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO:1 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:6; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 11, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 19; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 17, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 19; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 13, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 21; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 13, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 23; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 15, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 21; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 15, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 23; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 11 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 25; or the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 17 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 25; Fusion proteins are provided.
[0015] In some embodiments of the present invention, a fusion protein is provided, wherein the anti-TIGIT antibody or antigen-binding fragment thereof is selected from a Fab, a Fab', a F(ab')2, a Fd, a Fv, a dAb, a complementarity determining region fragment, a single chain antibody, a humanized antibody, a chimeric antibody, and a diabody.
[0016] In some embodiments of the invention, a fusion protein is provided, wherein the anti-TIGIT antibody is derived from a species other than mouse, for example comprising non-CDR regions derived from a human antibody.
[0017] In some embodiments of the present invention, a fusion protein is provided in which the heavy chain constant region of the anti-TIGIT antibody is an Ig gamma-1 chain C region (NCBI accession number P01857, etc.) or an Ig gamma-4 chain C region (NCBI accession number P01861.1, etc.), and the light chain constant region is an Ig kappa chain C region (NCBI accession number P01834, etc.).
[0018] In some embodiments of the present invention, fusion proteins are provided that have a higher binding affinity for the ligand CD155-hFc-biotin than the control antibody RG6058 (hG4).
[0019] In some embodiments of the invention, the fusion protein has an EC 50 and preferably said EC 50 is measured by indirect ELISA.
[0020] In some embodiments of the invention, the fusion protein has an EC value of less than 0.3 nM, less than 0.4 nM, less than 0.5 nM, or less than 0.6 nM for TGF-β1, TGF-β2, and / or TGF-β3. 50 and preferably said EC 50 is measured by indirect ELISA.
[0021] In some embodiments of the present invention, a fusion protein is provided, wherein the anti-TIGIT antibody is an antibody produced by hybridoma cell line LT019, deposited at the China Center for Type Culture Collection (CCTCC) under CCTCC number C2020208.
[0022] In some embodiments of the present invention, the heavy chain constant region of the anti-TIGIT antibody comprises the following combination of mutations based on the EU numbering system: L234A and L235A; L234A and G237A; L235A and G237A; or L234A, L235A, and G237A; A fusion protein is provided having one of the following:
[0023] In some embodiments of the present invention, the second protein functional domain is a TGF-β receptor, an extracellular domain thereof, or a truncated fragment of the extracellular domain of a TGF-β receptor having TGF-β receptor function; Preferably, the TGF-β receptor is TGF-βRI, TGF-βRII, or TGF-βRIII, or the extracellular domain of TGF-βRI, TGF-βRII, or TGF-βRIII, or a truncated fragment of the extracellular domain of TGF-βRI, TGF-βRII, or TGF-βRIII; Preferably, the second protein functional region comprises an amino acid sequence of any one of SEQ ID NOs: 33 to 39; Fusion proteins are provided.
[0024] In some embodiments of the present invention, a fusion protein is provided, wherein the heavy chain of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO:27 or SEQ ID NO:31, and the light chain comprises the amino acid sequence of SEQ ID NO:29.
[0025] In some embodiments of the invention, a fusion protein is provided, wherein the first protein functional domain and the second protein functional domain are linked directly or via a linker fragment.
[0026] In some embodiments of the invention there is provided a fusion protein, wherein the linker fragment is (GGGGS)n or (GGGGS)nG, where n is a positive integer, preferably n is 1, 2, 3, 4, 5, or 6.
[0027] In some embodiments of the invention, a fusion protein is provided, wherein the number of said first protein functional domains and said second protein functional domains is independently one, two or more.
[0028] In some embodiments of the present invention, a fusion protein is provided, wherein the TGF-β receptor or an extracellular fragment thereof is linked to the C-terminus of the heavy chain of the anti-TIGIT antibody.
[0029] The present invention relates to The first protein functional domain that targets TIGIT; and a second protein functional domain with TGF-β binding activity; A fusion protein comprising: the number of said first protein functional regions is 1 and the number of said second protein functional regions is 2; the first protein functional domain is an anti-TIGIT antibody or an antigen-binding fragment thereof, and the second protein functional domain is a TGF-β receptor, an extracellular domain thereof, or a truncated fragment of the extracellular domain of a TGF-β receptor having TGF-β receptor function; the heavy chain of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO:27 or SEQ ID NO:31, and the light chain comprises the amino acid sequence of SEQ ID NO:29; the second protein functional domain comprises the amino acid sequence of SEQ ID NO:33; the second protein functional region is linked to the C-terminus of the heavy chain of the anti-TIGIT antibody via a linker fragment; Preferably, the linker fragment comprises the amino acid sequence of SEQ ID NO: 44; Concerning fusion proteins.
[0030] In some embodiments of the invention, the fusion protein is used for the treatment and / or prevention of tumors, Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B-cell lymphoma, plasmacytoma, renal cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.
[0031] In a broad sense, the fusion proteins of the present invention may be referred to as antibodies.
[0032] Another aspect of the invention pertains to an isolated nucleic acid molecule encoding the fusion protein of any of the embodiments of the invention.
[0033] Yet another aspect of the present invention pertains to a vector comprising the isolated nucleic acid molecule of the present invention.
[0034] Yet another aspect of the invention relates to a host cell comprising the isolated nucleic acid molecule of the invention or the vector of the invention.
[0035] Yet another aspect of the present invention relates to a conjugate comprising a fusion protein moiety and a conjugated moiety, wherein the fusion protein moiety is a fusion protein of any of the embodiments of the present invention, and the conjugated moiety is a detectable label, preferably the conjugated moiety is a radioisotope, a fluorescent substance, a luminescent substance, a colored substance, or an enzyme.
[0036] In some embodiments of the invention, the conjugate is used for the treatment and / or prevention of a tumor; Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B-cell lymphoma, plasmacytoma, renal cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer.
[0037] Yet another aspect of the present invention relates to the use of the fusion protein of the present invention or the complex of the present invention in the preparation of a kit for detecting the presence or concentration of TIGIT and / or TGF-β in a sample.
[0038] Yet another aspect of the present invention relates to a pharmaceutical composition comprising the fusion protein of any of the embodiments of the present invention or the complex of the present invention, said pharmaceutical composition optionally further comprising a pharmacologically acceptable carrier and / or excipient.
[0039] In some embodiments of the present invention, the pharmaceutical composition further comprises one or more anti-tumor chemotherapeutic agents, preferably, the anti-tumor chemotherapeutic agent is a tyrosine kinase inhibitor, more preferably, the anti-tumor chemotherapeutic agent is anlotinib or a pharmacologically acceptable salt thereof (such as the hydrochloride salt), or lenvatinib or a pharmacologically acceptable salt thereof (such as the mesylate salt).
[0040] In some embodiments of the present invention, there is provided a pharmaceutical composition, wherein a unit dose of the pharmaceutical composition is 100 mg to 1500 mg, 200 mg to 1000 mg, 200 mg to 800 mg, 300 mg to 600 mg, 400 mg to 500 mg, or 450 mg based on the mass of the fusion protein.
[0041] In some embodiments of the invention, the pharmaceutical composition is an injectable formulation.
[0042] Yet another aspect of the present invention is A combination product comprising a first product and a second product in separate packages, the first article of manufacture comprises a fusion protein of any embodiment of the invention, a conjugate of the invention, or a pharmaceutical composition of any embodiment of the invention; the second product comprises one or more anti-tumor chemotherapeutic agents, preferably the anti-tumor chemotherapeutic agent is a tyrosine kinase inhibitor, more preferably the anti-tumor chemotherapeutic agent is anlotinib or a pharmacologically acceptable salt thereof (such as the hydrochloride salt), or lenvatinib or a pharmacologically acceptable salt thereof (such as the mesylate salt); Preferably, said first product and said second product independently further comprise one or more pharmacologically acceptable auxiliary materials; Preferably, said combination product further comprises a package insert; Concerning combination products.
[0043] In some embodiments of the present invention, a combination product is provided, wherein the unit dose of the first product is 100 mg to 1500 mg, 200 mg to 1000 mg, 200 mg to 800 mg, 300 mg to 600 mg, 400 mg to 500 mg, or 450 mg based on the mass of the fusion protein.
[0044] In some embodiments of the invention, a combination product is provided, wherein the unit dose of the second product is from 0.1 mg to 100 mg, from 0.5 mg to 50 mg, from 1 mg to 20 mg, from 2 mg to 15 mg, from 4 mg to 12 mg, or from 8 mg to 12 mg by weight of active ingredient.
[0045] In some embodiments of the invention, a therapeutic combination is provided, wherein said first product and said second product are independently injectables.
[0046] Yet another aspect of the invention is the use of a fusion protein according to any of the embodiments of the invention or a complex of the invention in the preparation of a medicament for the treatment and / or prevention of a tumor, comprising Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B-cell lymphoma, plasmacytoma, renal cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer; Regarding use.
[0047] Yet another aspect of the present invention is a method for treating and / or preventing a tumor, comprising administering to a subject in need of said treatment and / or prevention an effective amount of a fusion protein of any of the embodiments of the present invention or a complex of the present invention; Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B-cell lymphoma, plasmacytoma, renal cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer; It concerns the method.
[0048] In some embodiments of the present invention, methods are provided that include administering an effective amount of a pharmaceutical composition of any of the embodiments of the present invention to a subject in need thereof before or after surgical treatment and / or before or after radiation therapy.
[0049] In some embodiments of the present invention, The unit dose of the fusion protein of the present invention is 0.1 to 100 mg, preferably 1 to 10 mg per kg of body weight, or the unit dose of the fusion protein is 10 to 1000 mg, preferably 50 to 500 mg, 100 to 400 mg, 150 to 300 mg, 150 to 250 mg, or 200 mg for each subject; Preferably, said dose is administered once every 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks, or 3 weeks; Preferably, the route of administration is intravenous infusion or intravenous injection; A method is provided.
[0050] The variable regions of the light and heavy chains determine antigen binding. The variable region of each chain contains three hypervariable regions called complementarity determining regions (CDRs), the CDRs of the heavy chain (H) including HCDR1, HCDR2, and HCDR3, and the CDRs of the light chain (L) including LCDR1, LCDR2, and LCDR3. In the present invention, the CDRs are defined by the IMGT numbering system (see Ehrenmann F, Kaas Q, and Lefranc M P., IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF.[J]. Nucleic acids research, 2009; 38(suppl_1):D301-D307).
[0051] The amino acid sequences of the CDRs of the following monoclonal antibodies are analyzed by technical means well known to those skilled in the art, for example according to the IMGT definition. The results are as follows: HCDR and LCDR of mouse TIGIT monoclonal antibody HCDR1: GHSFTSDYA (SEQ ID NO: 3) HCDR2: ISYSDST (SEQ ID NO: 4) HCDR3: ARLDYGNYGGAMDY (SEQ ID NO:5) LCDR1: QHVSTA (SEQ ID NO: 8) LCDR2: SAS (SEQ ID NO: 9) LCDR3: QQHYITPWT (SEQ ID NO: 10)
[0052] The three HCDRs and three LCDRs of the humanized TIGIT monoclonal antibody are identical to those of the murine TIGIT monoclonal antibody.
[0053] In the present invention, unless otherwise defined, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Also, the laboratory procedures of cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are routine procedures widely used in the corresponding fields. Meanwhile, in order to facilitate understanding of the present invention, the definitions and explanations of relevant terms are provided below.
[0054] As used herein, EC 50 The term refers to the concentration for 50% of the maximal effect, i.e., the concentration capable of producing 50% of the maximal effect.
[0055] The term "antibody" as used herein refers to an immunoglobulin molecule that generally consists of two pairs of polypeptide chains, each pair having one "light" (L) chain and one "heavy" (H) chain. Antibody light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon. Antibody isotypes are defined as IgM, IgD, IgG, IgA, and IgE. In the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chains further include a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains, CH1, CH2, and CH3. Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, for example, the binding of various cells of the immune system (such as effector cells) to the first component (C1q) of the classical complement system. The VH and VL regions can be further divided into hypervariable regions (called complementarity determining regions (CDRs)), with conserved regions called framework regions (FRs) distributed between the hypervariable regions. Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of each heavy / light chain pair (VH and VL) form the antigen-binding site.The assignment of amino acids to regions or domains is based on Bethesda Md, Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, (1987 and 1991)) or Chothia & Lesk J. Mol. Biol., 1987; 196:901-917; Chothia et al., Nature, 1989; 342:878-883, or the definitions in the IMGT numbering system (see definitions in Ehrenmann F, Kaas Q, Lefranc M P., IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF.[J]. Nucleic acids research, 2009; 38(suppl_1):D301-D307).
[0056] The term "antibody" is not limited by any particular method for producing the antibody. For example, antibodies include recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibody may be of various isotypes, such as IgG (e.g., subtypes IgG1, IgG2, IgG3, or IgG4), IgA1, IgA2, IgD, IgE, or IgM.
[0057] The term "mAb" or "monoclonal antibody" as used herein refers to an antibody or antibody fragment that is derived from a group of highly homologous antibody molecules, i.e., from a group of identical antibody molecules except for natural mutations that may occur naturally. Monoclonal antibodies are highly specific to a single epitope on an antigen. Unlike monoclonal antibodies, polyclonal antibodies usually contain at least two or more different antibodies that generally recognize different epitopes on an antigen. Monoclonal antibodies can generally be obtained using hybridoma technology first reported by Kohler et al. (Kohler G, Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity.[J]. Nature, 1975; 256(5517):495), but can also be obtained using recombinant DNA technology (see, e.g., U.S. Pat. No. 4,816,567).
[0058] The term "humanized antibody" as used herein refers to an antibody or antibody fragment obtained when the whole or part of the CDRs of a human immunoglobulin (receptor antibody) are replaced with the CDRs of a non-human antibody (donor antibody), which may be a non-human (e.g. mouse, rat, or rabbit) antibody having the expected specificity, affinity, or reactivity. Furthermore, some amino acid residues in the framework region (FR) of the receptor antibody can also be replaced with the corresponding amino acid residues of the non-human antibody or other antibodies to further improve or optimize the performance of the antibody. For further details on humanized antibodies, see, e.g., Jones et al., Nature, 1986; 321:522-525; Reichmann et al., Nature, 1988; 332:323-329; Presta, Curr. Op. Struct. Biol., 1992; 2:593-596; and Clark, Immunol. Today, 2000; 21:397-402. In some cases, the antigen-binding fragment of an antibody is a diabody, H and V L The domains are expressed on a single polypeptide chain. However, due to the short linker used, pairing of the two domains on the same chain is not possible. Instead, the domains pair with complementary domains on the other chain, generating two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA, 1993; 90:6444-6448 and Poljak RJ et al., Structure, 1994; 2:1121-1123).
[0059] The fusion protein described herein is a protein product of two genes co-expressed by DNA recombination.Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art and are described, for example, in Chapters 5-8 and 15 of Antibodies: A Laboratory Manual, Cold Spring Harbor Press.
[0060] As used herein, the term "single chain variable fragment (ScFv)" refers to an antibody heavy chain variable fragment (V H ) and the antibody light chain variable region (V L ) linked by a linker. L and V H The domains are paired to form monovalent molecules with a linker that allows them to produce a single polypeptide chain (see, e.g., Bird et al., Science, 1988; 242:423-426 and Huston et al., Proc. Natl. Acad. Sci. USA, 1988; 85:5879-5883). Such scFv molecules may have the following general structure: NH2-V L -Linker fragment-V H -COOH or NH2-V H -Linker fragment-V L -COOH. A suitable linker in the prior art consists of a repeat of the amino acid sequence GGGGS, or a variant thereof. For example, a linker having the amino acid sequence (GGGGS)4 may be used, or a variant thereof (Holliger et al., Proc. Natl. Acad. Sci. USA, 1993; 90:6444-6448). Other linkers that can be used in the present invention are described in Alfthan et al., Protein Eng., 1995; 8:725-731, Choi et al., Eur. J. Immunol., 2001; 31:94-106, Hu et al., Cancer Res., 1996; 56:3055-3061, Kipriyanov et al., J. Mol. Biol., 1999; 293:41-56, and Roovers et al., Cancer Immunology, Immunotherapy, 2001, 50(1):51-59.
[0061] The term "isolated" as used herein refers to being obtained by artificial means from a natural state. When a particular "isolated" substance or component occurs in nature, it may be that the change occurs in its natural environment, or that it is isolated from the natural environment, or both. For example, if a particular non-isolated polynucleotide or polypeptide naturally occurs in a particular animal organism, and the same polynucleotide or polypeptide is isolated in high purity from such a natural state, it is called an isolated polynucleotide or polypeptide. The term "isolated" does not exclude the presence of artificial or synthetic substances or other impurities that do not affect the activity of the substance.
[0062] The term "vector" as used herein refers to a nucleic acid vehicle into which a polynucleotide can be inserted. If the vector allows expression of a protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction, or transfection so that the genetic material element carried by the vector can be expressed in the host cell. Vectors are well known to those skilled in the art, and examples include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); phages, such as lambda phage or M13 phage; and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (such as lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex viruses), poxviruses, baculoviruses, papilloma viruses, and papova viruses (such as SV40). The vector may contain various elements for regulating expression, examples of which include, but are not limited to, a promoter sequence, a transcription initiation sequence, an enhancer sequence, a selection element, and a reporter gene. Furthermore, the vector may contain a replication origin.
[0063] The term "host cell" as used herein refers to a cell into which a vector can be introduced, including, but not limited to, a prokaryotic cell, such as E. coli or Bacillus subtilis; a fungal cell, such as a yeast cell or Aspergillus; an insect cell, such as an S2 Drosophila cell or Sf9; or an animal cell, such as a fibroblast, a CHO cell, a GS cell, a COS cell, an NSO cell, a HeLa cell, a BHK cell, a HEK293 cell, or a human cell.
[0064] In the present invention, the term "ADCP" refers to antibody-dependent cellular phagocytosis. The Fc fragment of an antibody that binds to a cell surface antigen binds to the Fc receptor of a phagocytically active cell such as a macrophage, thereby mediating phagocytosis of the antibody-bound cell by the phagocyte.
[0065] In the present invention, the term "ADCC" refers to antibody-dependent cell-mediated cytotoxicity, in which the Fab fragment of an antibody binds to an epitope on a virus-infected cell or tumor cell, and the Fc fragment of the antibody binds to an Fc receptor (FcR) on the surface of a killer cell (such as a NK cell or macrophage), mediating the direct killing of the target cell by the killer cell.
[0066] In the present invention, the term "CDC" refers to complement-dependent cytotoxicity. When an antibody specifically binds to a corresponding antigen on the cell membrane surface, a complex is formed and the complement system is activated. MAC is then formed on the target cell surface, which results in subsequent lysis of the target cell. Complement can cause the lysis of various bacteria and other pathogenic organisms, and is an important defense mechanism against infection by pathogenic organisms.
[0067] As used herein, the term "specifically binds" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its target antigen. In some embodiments, an antibody that specifically binds to an antigen (or an antibody specific for an antigen) is one in which the antibody binds to the target antigen at a concentration of about 10-5 Less than M, e.g., about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 Affinity (K D ) means that the antibody binds to the antigen.
[0068] As used herein, "K D The term "dissociation equilibrium constant" refers to the dissociation equilibrium constant of a specific antibody-antigen interaction and is used to describe the binding affinity between an antibody and an antigen. A small dissociation equilibrium constant indicates strong antibody-antigen binding and high affinity between the antibody and the antigen. In general, antibodies have a dissociation equilibrium constant of about 10 -5 Less than M, e.g., about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The dissociation equilibrium constant (K D ) to bind to antigens (such as TIGIT proteins). D can be determined using methods known to those of skill in the art, for example, using the Fortebio system.
[0069] As used herein, the terms "monoclonal antibody" and "mAb" have the same meaning and can be used interchangeably. The terms "polyclonal antibody" and "pAb" have the same meaning and can be used interchangeably. Also, herein, amino acids are generally represented using one-letter or three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0070] As used herein, the term "pharmacologically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient and is well known in the art (e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 1999). thed. Pennsylvania: Mack Publishing Company, 1995), examples of which include, but are not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, a non-limiting example of a pH adjuster is phosphate buffer, a non-limiting example of a surfactant is a cationic, anionic, or non-ionic surfactant, such as Tween-80, and a non-limiting example of an ionic strength enhancer is sodium chloride.
[0071] The term "effective amount" as used herein refers to an amount sufficient to obtain or at least partially obtain a desired effect. For example, a prophylactically effective amount for a disease (such as a tumor) refers to an amount sufficient to prevent, inhibit or delay the onset of the disease (such as a tumor), and a therapeutically effective amount refers to an amount sufficient to cure or at least partially inhibit the disease or its complications in a patient suffering from the disease. Determining such an effective amount is undoubtedly within the capabilities of a person skilled in the art. For example, an effective amount for therapeutic purposes depends on the severity of the disease to be treated; the overall state of the patient's own immune system; the general condition of the patient, such as age, weight and sex; the route of administration; and other treatments performed at the same time; etc.
[0072] In the present invention, the terms "first" (e.g., a first protein functional domain or a first product) and "second" (e.g., a second protein functional domain or a second product) are used for expressive distinction or clarity, unless otherwise specified, and do not have a typical sequential meaning.
[0073] Beneficial Effects of the Invention The present invention achieves one or more of the following technical effects (1) to (9). (1) The fusion proteins of the present invention (e.g., TF01 or TF02) are capable of simultaneously inhibiting TIGIT and reducing TGF-β concentrations. (2) The fusion protein of the present invention (e.g., TF01 or TF02) can bind to TIGIT with high specificity, can block the binding of TIGIT to CD155 with high effectiveness, and can specifically alleviate the immunosuppression of TIGIT in living organisms. (3) The fusion protein of the present invention (e.g., TF01 or TF02) can bind to TGF-β with high specificity, can block the binding of TGF-β to the TGF-β receptor with high efficiency, and can specifically alleviate immune suppression caused by TGF-β in an organism and activate the immune response. (4) The fusion protein of the present invention has high potential for the preparation of antitumor drugs. (5) The first protein functional domain and the second protein functional domain of the fusion protein of the present invention have a synergistic effect, which is superior to that of a fusion protein in which either protein functional domain is used alone. (6) The fusion protein of the present invention, particularly TF01, has completely eliminated its binding activity to the Fc receptors FcγRI, FcγRIIb, FcγRIIa_H131, and / or FcγRIIa_R131, FcγRIIIa_V158, and / or FcγRIIIa_F158, and has eliminated its ADCC activity or ADCP activity. (7) The fusion protein of the present invention, particularly TF01, is completely devoid of binding activity to complement C1q and is completely devoid of CDC activity. (8) The fusion proteins of the present invention, especially both TF01 and TF02, can effectively block the immunosuppression of immune cells induced by TIGIT and induce IL-2 secretion in cells. (9) The fusion protein of the present invention, especially TF01, can effectively block the immunosuppression of immune cells induced by TGF-β and induce cellular INF-γ secretion. [Brief description of the drawings]
[0074] [Figure 1]FIG. 1 shows an analysis of the binding activity of TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) to the antigen TIGIT-mFc. [Diagram 2] FIG. 2 is an analysis of the binding activity of TF01, TF02, and TGF-βRII-mFc to TGF-β1. [Diagram 3] FIG. 3 is an analysis of the binding activity of TF01, TF02, and TGF-βRII-mFc to TGF-β2. [Figure 4] FIG. 4 is an analysis of the binding activity of TF01, TF02, and TGF-βRII-mFc to TGF-β3. [Diagram 5] FIG. 5 is an analysis of the activity of a fusion protein of anti-TIGIT antibody and TGF-βR to compete with TGF-βRII-His-biotin for binding to human TGF-β1. [Figure 6] FIG. 6 is an analysis of the activity of a fusion protein of anti-TIGIT antibody and TGF-βR to compete with TGF-βRII-His-biotin for binding to human TGF-β3. [Figure 7] FIG. 7 is an analysis of the activity of fusion proteins of anti-TIGIT antibodies and TGF-βR in competing with human CD155-hFc-biotin for binding to human TIGIT-mFC. [Figure 8] FIG. 8 shows an analysis of the binding activity of a fusion protein of anti-TIGIT antibody and TGF-βR to TIGIT on the surface of 293T-TIGIT membrane. [Figure 9] FIG. 9 is an analysis of TF01, which competes with CD155 for binding to the antigen TIGIT on the cell membrane surface. [Figure 10] FIG. 10 is an analysis of TF01, which competes with CD112 for binding to the antigen TIGIT on the cell membrane surface. [Figure 11] FIG. 11 is an analysis of the affinity constant of TF01 for FcγRI. [Figure 12] FIG. 12 is an analysis of the affinity constant of 26B12H2L2 (hG1WT) for FcγRI. [Figure 13]FIG. 13 is an analysis of the affinity constant of TF01 for FcγRIIIa_V158. [Figure 14] FIG. 14 is an analysis of the affinity constant of 26B12H2L2 (hG1WT) for FcγRIIIa_V158. [Figure 15] FIG. 15 is an analysis of the affinity constant of TF01 for FcγRIIIa_F158. [Figure 16] FIG. 16 is an analysis of the affinity constant of 26B12H2L2 (hG1WT) for FcγRIIIa_F158. [Figure 17] FIG. 17 is an analysis of the affinity constant of TF01 for FcγRIIa_H131. [Figure 18] FIG. 18 is an analysis of the affinity constant of 26B12H2L2 (hG1WT) for FcγRIIa_H131. [Figure 19] FIG. 19 is an analysis of the affinity constant of TF01 for FcγRIIa_R131. [Figure 20] FIG. 20 is an analysis of the affinity constant of 26B12H2L2 (hG1WT) for FcγRIIa_R131. [Figure 21] FIG. 21 is an analysis of the affinity constant of TF01 for FcγRIIb. [Figure 22] FIG. 22 is an analysis of the affinity constant of 26B12H2L2 (hG1WT) for FcγRIIb. [Figure 23] FIG. 23 is an analysis of the affinity constant of TF01 for C1q. [Figure 24] FIG. 24 is an analysis of the affinity constant of 26B12H2L2 (hG1WT) for C1q. [Diagram 25] FIG. 25 is an analysis of the ADCP effects of RG6058(hG1WT), RG6058(hG4WT), 26B12H2L2(hG1WT), and TF01. [Figure 26]FIG. 26 shows an evaluation of the blocking activity of a fusion protein of anti-TIGIT antibody and TGF-βR on CD112 inhibition of IL-2 secretion in a Jurkat-TIGIT and THP-1 cell coculture system. [Figure 27] FIG. 27 shows an evaluation of the blocking activity of a fusion protein of an anti-TIGIT antibody and TGF-βR on CD155 inhibition of IL-2 secretion in a Jurkat-TIGIT and THP-1 cell coculture system. [Figure 28] FIG. 28 shows an evaluation of the biological activity of a fusion protein of an anti-TIGIT antibody and TGF-βR in promoting IL-2 secretion in a co-culture system of Jurkat-TIGIT and HT1080-aCD3scFv cells. [Figure 29] FIG. 29 is an evaluation of the blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on TGF-β1 inhibition of IFN-γ secretion during the course of PBMC secondary immune response to CMV antigen. [Diagram 30] Figure 30 shows the efficacy of anti-TIGIT antibody and TGF-βR fusion protein for the treatment of MDA-MB-231 xenograft tumors in Scid Beige mouse model. Results are shown as mean ± standard error and subjected to two-way ANOVA (Bonferroni test). *p<0.05, **p<0.01, and ***p<0.001; compared with isotype control. [Diagram 31] FIG. 31 shows the effect of anti-TIGIT antibody and TGF-βR fusion protein on body weight in a Scid Beige mouse model bearing MDA-MB-231 xenograft tumors. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0075] Deposited biological material: The hybridoma cell line LT019 (TIGIT-26B12) was deposited at the China Center for Type Culture Collection (CCTCC) under CTCCC number C2020208 on October 23, 2020. The address of the depository institution is Wuhan University, Wuhan, Postal Code 430072, People's Republic of China.
[0076] The present invention relates to the following sequences 1 to 48. 1. Amino acid sequence of 26B12VH EVQLQESGPGLVKPSQSLSLTCTVTGHSFTSDYAWNWIRQFPGNRLEWMGYISYSDSTNYNPSLKSRISITRDTSKNQFFLQMNSVTTEDTATYYCARLDYGNYGGAMDYWGQGTSVTVSS (SEQ ID NO: 1) 2. Nucleotide sequence of 26B12VH GAGGTGCAGCTGCAGGAGTCTGGACCTGGCCTGGTGAAACCTCTCAGTCTCTGTCCCTCACCTGCACTGTCACTGGCCACTCATTCACCAGTGATTATGCCTGGAACTGGATCCGGCAGTTTCCAGGAAACAGACTGGAGTGGATGGGCTACATAAGCTACAGTGATAGCACTAACTACAACCC ATCTCTCAAAAGTCGAATCTCTATCACTCGAGACACATCCAAGAACCAGTTCTTCTTGCAGATGAATTCTGTGACTACTGAGGACACAGCCACATATTACTGTGCAAGATTGGACTATGGTAACTACGGTGGGGCTATGGACTACTGGGGTCAAGGGACCTCAGTCACCGTCTCCTCA (SEQ ID NO: 2) 3. HCDR1: GHSFTSDYA (SEQ ID NO: 3) 4. HCDR2: ISYSDST (SEQ ID NO:4) 5. HCDR3: ARLDYGNYGGAMDY (SEQ ID NO:5) 6. Amino acid sequence of 26B12VL DIVLTQSHEFMSTSLRDRVSITCKSSQHVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVKAEDLAVYYCQQHYITPWTFGGGTKLEIK (SEQ ID NO: 6) 7. Nucleotide sequence of 26B12VL GATATTGTGCTAACTCAGTCTCACGAATTCATGTCCACCTCATTACGAGACAGGGTCAGCATCACCTGCAAATCCAGTCAACATGTGAGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTACTCGGCATCCTACCGGTA CACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACGGATTTCACTTTCACCATCAGCAGTGTGAAGGCTGAAGACCTGGCAGTTTATTACTGTCAGCAACATTATATTACTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATAAAA (SEQ ID NO: 7) 8. LCDR1: QHVSTA (SEQ ID NO: 8) 9. LCDR2: SAS (SEQ ID NO: 9) 10. LCDR3: QQHYITPWT (SEQ ID NO: 10) 11. Amino acid sequence of 26B12H1VH DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWNWIRQFPGKGLEWIGYISYSDSTNYNPSLKSRITISRDTSKNQFFLQLNSVTAADTATYYCARLDYGNYGGAMDYWGQGTSVTVSS (SEQ ID NO: 11) 12. Nucleotide sequence of 26B12H1VH GATGTGCAGCTGCAGGAGAGCGGCCCCGGACTGGTGAAGCCTTCCCAGACCCTGTCTCTGACCTGTACAGTGTCTGGCCACAGCTTCACATCCGACTACGCCTGGAACTGGATCAGGCAGTTTCCAGGCAAGGGCCTGGAGTGGATCGGCTACATCTCTTATAGCGACTCCACCAACTATAATCCCTCTCTGAAGAGCCGGATCACCATCAGCAGAGATACATCCAAGAACCAGTTCTTTCTGCAGCTGAACAGCGTGACAGCCGCCGACACCGCCACATACTATTGCGCCCGGCTGGACTACGGCAATTATGGCGGAGCCATGGATTACTGGGGCCAGGGCACCTCCGTGACAGTGAGCTCC(SEQ ID NO: 12) 13. Amino acid sequence of 26B12H2 VH DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWSWIRQPPGKGLEWIGYISYSDSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYGNYGGAMDYWGQGTSVTVSS(SEQ ID NO: 13) 14. Nucleotide sequence of 26B12H2 VH GATGTGCAGCTGCAGGAGTCTGGCCCAGGACTGGTGAAGCCAAGCCAGACCCTGTCCCTGACCTGTACAGTGTCCGGCCACTCTTTTACAAGCGACTACGCCTGGTCTTGGATCAGGCAGCCCCCTGGCAAGGGACTGGAGTGGATCGGCTACATCTCCTATTCTGACAGCACCAACTATAATCCCTCCCTGAAGTCTCGGGTGACCATCTCTAGAGATACAAGCAAGAACCAGTTCTCCCTGAAGCTGAGCTCCGTGACCGCAGCAGACACAGCCGTGTACTATTGCGCCCGGCTGGACTACGGCAATTATGGCGGAGCCATGGATTACTGGGGCCAGGGCACCAGCGTGACAGTGTCTAGC(SEQ ID NO: 14) 15. Amino acid sequence of 26B12H3 VH DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWSWIRQPPGKGLEWIGYISYSDSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARLDYGNYGGAMDYWGQGTSVTVSS (SEQ ID NO: 15) 16. Nucleotide sequence of 26B12H3VH GATGTGCAGCTGCAGGAGTCTGGCCCAGGACTGGTGAAGCCAAGCCAGACCCTGTCCCTGACCTGTACAGTGTCCGGCCACTCTTTTACAAGCGACTACGCCTGGTCTTGGATCAGACAGCCCCCTGGCAAGGGACTGGAGTGGATCGGCTACATCTCCTATTCTGACAGCACCAACTATAATCC CTCCCTGAAGTCTAGAGTGACCATCTCTGTGGATACAAGCAAGAACCAGTTCTCCCTGAAGCTGAGCTCCGTGACCGCAGCAGACACAGCCGTGTACTATTGCGCCCGGCTGGACTACGGCAATTATGGCGGAGCCATGGATTACTGGGGCCAGGGCACCAGCGTGACAGTGTCTAGC (SEQ ID NO: 16) 17. Amino acid sequence of 26B12H4VH DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWNWIRQFPGKGLEWMGYISYSDSTNYNPSLKSRITISRDTSKNQFFLQLNSVTAADTATYYCARLDYGNYGGAMDYWGQGTSVTVSS (SEQ ID NO: 17) 18. Nucleotide sequence of 26B12H4VH GATGTGCAGCTGCAGGAGAGCGGCCCCGGACTGGTGAAGCCTTCCCAGACCCTGTCTCTGACCTGTACAGTGTCTGGCCACAGCTTCACATCCGACTACGCCTGGAACTGGATCAGGCAGTTTCCAGGCAAGGGCCTGGAGTGGATGGGCTACATCTCTTATAGCGACTCCACCAACTATAATCC CTCTCTGAAGAGCCGGATCACCATCAGCAGAGATACATCCAAGAACCAGTTCTTTCTGCAGCTGAACAGCGTGACAGCCGCCGACACCGCCACATACTATTGCGCCCGGCTGGACTACGGCAATTATGGCGGAGCCATGGATTACTGGGGCCAGGGCACCTCCGTGACAGTGAGCTCC (SEQ ID NO: 18) 19. Amino acid sequence of 26B12L1VL DIQMTQSPKSLSTSVGDRVTITCRSSQHVSTAVAWYQQKPGKSPKLLIYSASYRYSGVPDRFSGSGSGTDFTFTISSVQPEDFATYYCQQHYITPWTFGGGTKLEIK (SEQ ID NO: 19) 20. Nucleotide sequence of 26B12L1VL GACATCCAGATGACCCAGTCCCCTAAGTCCCTGTCTACAAGCGTGGGCGATCGGGTGACCATCACATGTAGAAGCTCCCAGCACGTGTCTACCGCAGTGGCATGGTACCAGCAGAAGCCAGGCAAGAGCCCTAAGCTGCTGATCTATTCCGCCTCTTACAGGTA TTCCGGAGTGCCAGACCGGTTTAGCGGCTCCGGCTCTGGCACCGATTTCACCTTTACAATCTCTAGCGTGCAGCCAGAGGACTTCGCCACATACTATTGCCAGCAGACTACATCACCCCATGGACCTTCGGCGGCGGCACAAAGCTGGAGATCAAG (SEQ ID NO: 20) 21. Amino acid sequence of 26B12L2VL DIQMTQSPSSLSASVGDRVTITCRSSQHVSTALAWYQQKPGKSPKLLIYSASSRYSGVPDRFSGSGSGTDFTFTISSLQPEDFATYYCQQHYITPWTFGGGTKLEIK (SEQ ID NO: 21) 22. Nucleotide sequence of 26B12L2VL GACATCCAGATGACCCAGTCCCCTAGCTCCCTGTCTGCCAGCGTGGGCGATAGGGTGACCATCACATGTAGATCTAGCCAGCACGTGTCTACAGCCCTGGCATGGTACCAGCAGAAGCCAGGCAAGAGCCCTAAGCTGCTGATCTACTCCGCCTCCTCTAGGTA TTCTGGAGTGCCAGACCGGTTTTCCGGCTCTGGCAGCGGCACCGATTTCACCTTTACAATCAGCTCCCTGCAGCCAGAGGACTTCGCCACATACTATTGCCAGCAGCACTATATCACCCCATGGACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG (SEQ ID NO: 22) 23. Amino acid sequence of 26B12L3VL DIQMTQSPSSLSASVGDRVTITCRASQHVSTALAWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYITPWTFGGGTKLEIK (SEQ ID NO: 23) 24. Nucleotide sequence of 26B12L3VL GACATCCAGATGACCCAGTCCCCTAGCTCCCTGAGCGCCTCCGTGGGCGATAGGGTGACCATCACATGTAGAGCCTCTCAGCACGTGAGCACAGCCCTGGCATGGTACCAGCAGAAGCCAGGCAAGGCCCCTAAGCTGCTGATCTATAGCGCCTCTAGCCTGCA GTCCGGAGTGCCATCTCGGTTCTCTGGCAGCGGCTCCGGAACCGACTTTACCCTGACAATCTCCTCTCTGCAGCCAGAGGATTTCGCCACATACTATTGCCAGCAGACTACATCACCCCATGGACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG (SEQ ID NO: 24) 25. Amino acid sequence of 26B12L4VL DIQMTQSPKSMSTSVGDRVTITCRSSQHVSTAVAWYQQKPGKSPKLLIYSASYRYSGVPDRFSGSGSGTDFTFTISSVQPEDFATYYCQQHYITPWTFGGGTKLEIK (SEQ ID NO: 25) 26. Nucleotide sequence of 26B12L4VL GACATCCAGATGACCCAGTCCCCTAAGTCCATGTCTACAAGCGTGGGCGACAGGGTGACCATCACATGTAGAAGCTCCCAGCACGTGTCTACCGCAGTGGCATGGTACCAGCAGAAGCCAGGCAAGAGCCCTAAGCTGCTGATCTATTCCGCCTCTTACAGGTA TTCCGGAGTGCCAGACCGGTTTAGCGGCTCCGGCTCTGGCACCGATTTCACCTTTACAATCTCTAGCGTGCAGCCAGAGGACTTCGCCACATACTATTGCCAGCAGACTACATCACCCCATGGACCTTCGGCGGCGGCACAAAGCTGGAGATCAAG (SEQ ID NO: 26) 27. Amino acid sequence of the heavy chain of 26B12H2L2 (hG4DM) DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWSWIRQPPGKGLEWIGYISYSDSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYGNYGGAMDYWGQ GTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC PPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG (SEQ ID NO: 27) 28. Nucleotide sequence of the heavy chain of 26B12H2L2 (hG4DM) 29. Amino acid sequence of the light chain of 26B12H2L2 (hG4DM) DIQMTQSPSSLSASVGDRVTITCRSSQHVSTALAWYQQKPGKSPKLLIYSASSRYSGVPDRFSGSGSGTDFTFTISSLQPEDFATYYCQQHYITPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 29) 30. Nucleotide sequence of the light chain of 26B12H2L2 (hG4DM) (SEQ ID NO:30) 31. Amino acid sequence of the heavy chain of 26B12H2L2 (hG1DM) DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWSWIRQPPGKGLEWIGYISYSDSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYGNYGGAMDYWGQG TSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 31) 32. Nucleotide sequence of the heavy chain of 26B12H2L2 (hG1DM) 33. Amino acid sequence of a truncated fragment of the extracellular domain of TGF-βRII IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD (SEQ ID NO: 33) 34. Amino acid sequence of TGF-βRI: (underlined part is the sequence of the extracellular domain) MEAAVAAPRPRLLLLVLAAAAAAAALLPGATA LQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEL AAVIAGPVCFVCISLMLMVYICHNRTVIHHRVPNEEDPSLDRPFISEGTTLKDLIYDMTTSGSGSGLPLLVQRTIARTIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM (SEQ ID NO: 34) 35. Amino acid sequence of the extracellular domain of TGF-βRI LQCFCHLCTKDNFTCVTDGLCFVSVTETTDKVIHNSMCIAEIDLIPRDRPFVCAPSSKTGSVTTTYCCNQDHCNKIELPTTVKSSPGLGPVEL (SEQ ID NO: 35) 36. Amino acid sequence of TGF-βRII: (underlined part is the sequence of the extracellular domain) MGRGLLRGLWPLHIVLWTRIAS TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK (SEQ ID NO: 36) 37. Amino acid sequence of the extracellular domain of TGF-βRII TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQ (SEQ ID NO: 37) 38. Amino acid sequence of TGF-βRIII: (underlined part is the sequence of the extracellular domain) MTSHYVIAIFALMSSCLATA GPEPGALCELSPVSASHPVQALMESFTVLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQREVTLHLNPISSVHIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVSEGSVVQFSSANFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKIARNIYIKVGEDQVFPPKCNIGKNFLSLNYLAEYLQPKAAEGCVMSSQPQNEEVHIIELITPNSNPYSAFQVDITIDIRPSQEDLEVVKNLILILKCKKSVNWVIKSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDIPSTQGNLVKWALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHTIPPELRILLDPGALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGEDGLPRPKDPVIPSIQLFPGLREPEEVQGSVDIALSVKCDNEKMIVAVEKDSFQASGYSGMDVTLLDPTCKAKMNGTHFVLESPLNGCGTRPRWSALDGVVYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDASLFTRPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQGVFSVPENGHVYVEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIENICPKDESVKFYSPKRVHFPIPQADMDKKRFSFVFKPVFNTSLLFLQCELTLCTKMEKHPQKLPKCVPPDEACTSLDASIIWAMMQNKKTFTKPLAVIHHEAESKEKGPSMKEPNPISPPIFHGLDTLTV MGIAFAAFVIGALLTGALWYIYSHTGETAGRQQVPTSPPASENSSAAHSIGSTQSTPCSSSSTA (SEQ ID NO: 38) 39. Amino acid sequence of the extracellular domain of TGF-βRIII (SEQ ID NO:39) 40. Amino acid sequence of the heavy chain of Tiragolumab EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYW GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 40) 41. Amino acid sequence of the light chain of tiragolumab DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 41) 42. Amino acid sequence of the heavy chain variable region of RG6058 (hG4) EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS (SEQ ID NO: 42) 43. Amino acid sequence of the light chain variable region of RG6058 (hG4) DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIK (SEQ ID NO: 43) 44. Amino acid sequence of the linker fragment GGGGSGGGGSGGGGSGGGGSG (SEQ ID NO: 44) 45. Amino acid sequence of the heavy chain of anti-HEL&TGFβ antibody (SEQ ID NO:45) 46. Amino acid sequence of the light chain of anti-HEL&TGFβ antibody DIELTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYTSQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSGSWPRTFGGGTKLDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 46) 47. Amino acid sequence of the heavy chain of RG6058(G1DM) EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYW GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 47) 48. Amino acid sequence of the light chain of RG6058(G1DM) DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 48)
[0077] Detailed Description The embodiments of the present invention are described below with reference to examples, but those skilled in the art will understand that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the present invention. In the examples, experimental procedures without specified conditions are carried out according to conventional conditions or conditions recommended by the manufacturer. All reagents or equipment used without manufacturer's specification are commercially available conventional products.
[0078] BALB / c mice were purchased from Guangdong Medical Laboratory Animal Center.
[0079] C57 mice were purchased from the Laboratory Animal Center of Guangzhou University of Chinese Medicine.
[0080] MDA-MB-231 cells and U87-MG cells were purchased from ATCC.
[0081] The positive control antibody, tiragolumab, is derived from an antibody described in WHO. Proposed INN: List 117. WHO Drug Information, 31(2): p104, 2017, and contains heavy and light chain amino acid sequences identical to the amino acid sequences of SEQ ID NOs: 40 to 41, respectively.
[0082] In the present invention, tiragolumab and RG6058 (hG1WT) are the same antibody.
[0083] The positive control antibody RG6058 (hG4) comprises a sequence derived from the antibody described in Chinese Patent Application Publication No. CN108290946(A), and comprises amino acid sequences of the heavy chain variable region and the light chain variable region that are identical to the amino acid sequences of SEQ ID NOs: 42 to 43, respectively.
[0084] Positive control antibody RG6058 (hG1DM) was prepared in the Akeso Biopharma laboratory with lot number 20180816. The amino acid sequence of its heavy chain is shown in SEQ ID NO:47 and the SEQ ID NO:48 of its light chain.
[0085] The variable region sequence of human anti-hen egg lysozyme IgG (anti-HEL, or human IgG; abbreviated as hIgG), which is an isotype control antibody in the examples of the present invention, is derived from Acierno et al. "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies" (Acierno et al., J Mol Biol., 2007; 374(1):130-46). hIgG1DM and hIgG4WT used in the examples are isotype control antibodies with anti-HEL having hG1DM and hG4WT constant region sequences, respectively, and were prepared in the laboratory of Akeso Biopharma.
[0086] Anti-HEL&TGFβ antibody was constructed by fusing TGFβRII to the C-terminus of the heavy chain of k-subtype anti-HEL antibody (human hG4DM). Preparation was performed in the Akeso Biopharma laboratory. The amino acid sequence of the heavy chain is shown in SEQ ID NO:45, and the amino acid sequence of the light chain is shown in SEQ ID NO:46.
[0087] TIGIT-mFc protein (Lot No. 20171110), TGF-βRII-mFc (Lot No. 20200528), CD155-hFc-biotin (Lot No. 20170721), CD155-mFc (Lot No. 20190726), and CD112-mFc (Lot No. 20190726) were all produced by Akeso Biopharma according to the published sequences. mFc represents the Fc protein fragment of mouse IgG, and hFc represents the Fc protein fragment of human IgG.
[0088] TGF-β1 protein was purchased from Sino Biologcal, catalog number LC13DE3108.
[0089] TGF-β2 protein was purchased from PeproTech, catalog number 0420345 E0620.
[0090] TGF-β3 protein was purchased from PeproTech, catalog number 0713410 A0219.
[0091] In the following examples of the present invention, the cell line 293T-TIGIT used was constructed by Akeso Biopharma. The cell line 293T-TIGIT was prepared by viral infection of HEK293T cells (Wuhan University) using a third generation lentivirus system (see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11):8463-8471). The lentivirus expression vector used here was plenti6.3 / V5-TIGITFL-BSD (TIGIT is Genebank ID: NP_776160.2; vector plenti6.3 / V5 TOPO was purchased from Invitrogen under catalog number K531520).
[0092] In the following examples of the present invention, the cell line CHO-K1-TIGIT used was constructed by Akeso Biopharma. The cell line CHO-K1-TIGIT was prepared by viral infection of CHO-K1 cells (Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences) using a third generation lentivirus system (see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11):8463-8471). The lentivirus expression vector used here was plenti6.3 / V5-TIGITFL-BSD (TIGIT is Genebank ID: NP_776160.2, and the vector plenti6.3 / V5 TOPO was purchased from Invitrogen under catalog number K531520).
[0093] In the following examples of the present invention, the cell line Jurkat-TIGIT used was constructed by Akeso Biopharma. The cell line Jurkat-TIGIT was prepared by viral infection of Jurkat cells (Cell Center, Chinese Academy of Sciences) using the third generation lentivirus system (see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11):8463-8471). The lentivirus expression vector used here was plenti6.3 / V5-TIGITFL-BSD (TIGIT is Genebank ID: NP_776160.2; vector plenti6.3 / V5 TOPO was purchased from Invitrogen under catalog number K531520).
[0094] In the following examples of the present invention, the cell line HT1080-aCD3scFv used was constructed by Akeso Biopharma Co., Ltd. The cell line HT1080-aCD3scFv was prepared by viral infection of HT-1080 cells (Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) using a third generation lentivirus system (see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11):8463-8471). The lentiviral expression vector used here was pCDH-aCD3scFv-Puro (the sequence of anti-CD3scFv was obtained from the anti-human CD3 Mus musculus OKT3 hybridoma antibody; the vector pCDH-CMV-MCS-EF1-Puro was purchased from Youbio under catalog number VT1480).
[0095] Example 1: Preparation of anti-TIGIT antibody 1. Preparation of hybridoma cell line LT019 The antigen used for preparation of anti-TIGIT antibody was human TIGIT-mFc (TIGIT had GenBank ID: NP_776160.2). The splenocytes of immunized mice were fused with mouse myeloma cells to prepare hybridoma cells. Using human TIGIT-hFc as an antigen, the hybridoma cells were screened by indirect ELISA to obtain hybridoma cells capable of secreting antibodies that specifically bind to TIGIT. The hybridoma cells obtained by screening were subjected to limiting dilution to obtain a stable hybridoma cell line. The above hybridoma cell line was named hybridoma cell line LT019, and the monoclonal antibody secreted from this cell line was named 26B12.
[0096] The hybridoma cell line LT019 (also known as TIGIT-26B12) was deposited at the China Center for Type Culture Collection (CCTCC) under CTCCC number C2020208 on October 23, 2020. The depository address is Wuhan University, Wuhan, Postal Code 430072, People's Republic of China.
[0097] 2. Preparation of anti-TIGIT antibody 26B12 The cell line LT019 prepared above was cultured in a chemically defined medium (CD medium, containing 1% penicillin-streptomycin) at 37°C / 5% CO2. After 7 days, the cell culture supernatant was collected, centrifuged at high speed, and vacuum filtered through a microfiltration membrane. The antibody 26B12 was obtained by purification using a HiTrap protein A HP column.
[0098] Example 2: Sequence analysis of anti-TIGIT antibody 26B12 According to the method described in the instruction manual for the Cell / Bacteria Total RNA Extraction Kit (Tiangen, Catalog No. DP430), mRNA was extracted from the cell line LT019 cultured in Example 1.
[0099] cDNA was synthesized and amplified by PCR according to the instructions for use with the Invitrogen SuperScript® III First-Strand Synthesis System for RT-PCR.
[0100] TA cloning was performed directly from the PCR amplification product according to the instructions for use of the pEASY-T1 Cloning Kit (Transgen, CT101).
[0101] The TA cloning product was directly sequenced, and the sequencing results are as follows:
[0102] The nucleotide sequence of the heavy chain variable region is 363 bp in length and is shown in SEQ ID NO: 2. The encoded amino acid sequence is 121 amino acids in length and is shown in SEQ ID NO: 1. The sequences of the heavy chain HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NOs: 3, 4, and 5, respectively.
[0103] The nucleotide sequence of the light chain variable region is 321 bp in length and is shown in SEQ ID NO: 7. The encoded amino acid sequence is 107 amino acids in length and is shown in SEQ ID NO: 6. The sequences of the light chain LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NO: 8, 9, and 10, respectively.
[0104] Example 3: Design and preparation of anti-human TIGIT humanized and mutant antibodies 1. Design of the light and heavy chains of anti-human TIGIT humanized antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4, and 26B12H4L4 Based on the three-dimensional crystal structure of human TIGIT protein and the sequence of antibody 26B12 obtained in Example 2, the variable region sequences of antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4, and 26B12H4L4 (antibody constant region sequences from NCBI database: heavy chain constant region is Ig gamma-1 chain C region, accession number P01857; light chain constant region is Ig kappa chain C region, accession number P01834) were designed.
[0105] The designed variable region sequences are shown in Table 1 below. [Table 2]
[0106] For the above eight antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4, and 26B12H4L4, the length of the nucleotide sequence of the heavy chain variable region was 363 bp, and the length of the encoded amino acid sequence was 121 aa; the length of the nucleotide sequence of the light chain variable region was 321 bp, and the length of the encoded amino acid sequence was 107 aa.
[0107] Furthermore, the above eight antibodies had the same HCDR1 to HCDR3 and LCDR1 to LCDR3. The sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NOs: 3, 4, and 5, respectively, and the sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NOs: 8, 9, and 10, respectively.
[0108] 2. Preparation of humanized antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4, and 26B12H4L4 All heavy chain constant regions were Ig gamma-1 chain C regions, accession number P01857, and all light chain constant regions were Ig kappa chain C regions, accession number P01834.
[0109] The heavy and light chain cDNAs of 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4, 26B12H2L4, and 26B12H4L4 were separately cloned into pUC57simple (provided by GenScript) vectors, pUC57simple-26B12H1, pUC57simple-26B12L1; pUC57simple-26B12H4, pUC57simple-26B12L1; pUC57simple-26B12H2, pUC57simple-26B12L2; pUC57simple-26B12H3, pUC57simple-26B12L2; pUC57simple-26B12H2, pUC57simple-26B12L3; pUC57simple-26B12H3, pUC57simple-26B12L3; pUC57simple-26B12H1, pUC57simple-26B12L4; and pUC57simple-26B12H4, pUC57simple-26B12L4; obtained.
[0110] Referring to the standard techniques described in Molecular Cloning: A Laboratory Manual (Second Edition), the heavy and light chain full-length genes synthesized by EcoRI and HindIII digestion were subcloned into expression vector pcDNA3.1 by digestion with restriction enzymes EcoRI and HindIII to obtain expression plasmids pcDNA3.1-26B12H1, pcDNA3.1-26B12L1, pcDNA3.1-26B12H4, pcDNA3.1-126B12H2, pcDNA3.1-26B12L2, pcDNA3.1-26B12H3, pcDNA3.1-26B12L3, and pcDNA3.1-26B12L4, and the heavy / light chain genes of the recombinant expression plasmids were further sequenced. Then, the corresponding light and heavy chain recombinant plasmids (pcDNA3.1-26B12H1 / pcDNA3.1-26B12L1, pcDNA3.1-26B12H4 / pcDNA3.1-26B12L1, pcDNA3.1-26B12H2 / pcDNA3.1-26B12L2, pcDNA3.1-26B12H3 / pcDNA3.1-26B12L2, pcDNA3.1-26B12H2 The designed gene combinations, including pcDNA3.1-26B12L3, pcDNA3.1-26B12H3 / pcDNA3.1-26B12L3, pcDNA3.1-26B12H1 / pcDNA3.1-26B12L4, and pcDNA3.1-26B12H4 / pcDNA3.1-26B12L4, were separately co-transfected into 293F cells, and the cultures were harvested and purified. After sequence confirmation, endotoxin-free expression plasmids were prepared and transiently transfected into HEK293 cells for antibody expression. After 7 days of culture, the cell cultures were harvested and affinity purified on a Protein A column to obtain humanized antibodies.
[0111] The humanized antibody 26B12H2L2 is also referred to herein as 26B12H2L2(hG1WT).
[0112] 3. Design of humanized antibodies 26B12H2L2(hG1DM) and 26B12H2L2(hG4DM) The inventors obtained humanized antibody 26B12H2L2(hG1DM) having a mutated constant region by introducing a point mutation from leucine to alanine (L234A) at position 234 (according to the EU numbering system; the same applies below) and a point mutation from leucine to alanine (L235A) at position 235 in the heavy chain constant region of 26B12H2L2. The amino acid sequence of the heavy chain 26B12H2(hG1DM) of 26B12H2L2(hG1DM) is shown in SEQ ID NO:31, and the amino acid sequence of the light chain is shown in SEQ ID NO:29.
[0113] The inventors used Ig gamma-4 chain C region (Accession: P01861.1) as the heavy chain constant region, introduced a point mutation from leucine to alanine at position 234 (L234A) and a point mutation from leucine to alanine at position 235 (L235A) in the heavy chain constant region of 26B12H2L2, while keeping the antibody variable region constant, to obtain humanized antibody 26B12H2L2(hG4DM) having a mutated constant region. The amino acid sequence of the heavy chain 26B12H2(hG4DM) of 26B12H2L2(hG4DM) is shown in SEQ ID NO:27, and the amino acid sequence of the light chain is shown in SEQ ID NO:29.
[0114] Humanized antibodies 26B12H2L2(hG1DM) and 26B12H2L2(hG4DM) were prepared by the method described in step 2 above.
[0115] Example 4: Sequence design and preparation of fusion protein of anti-TIGIT antibody and TGF-βR 1. Sequence Design The structure of the fusion protein of anti-TIGIT antibody and TGF-βR is shown in Table 2 below. [Table 3]
[0116] The TGF-β receptor portion has two peptide chains, each of which is linked to the C-terminus of the heavy chain of the IgG portion via a linker fragment.
[0117] 2. Antibody Expression and Purification The heavy and light chain cDNA sequences of TF01 and TF02 were separately cloned into the vector pUC57simple (provided by Genscript) to obtain the plasmids pUC57simple-TF01H and pUC57simple-TF02H, or pUC57simple-TF01L and pUC57simple-TF02L, respectively.
[0118] Plasmids pUC57simple-TF01H / pUC57simple TF01L and pUC57simple-TF02H / pUC57simple TF02L were digested (HindIII and EcoRI), and the heavy and light chains isolated by electrophoresis were subcloned separately into vector pcDNA3.1, and the recombinant plasmids were extracted and co-transfected into 293F cells. After 7 days of cell culture, the culture was separated by high-speed centrifugation, and the supernatant was concentrated and loaded onto a HiTrap MabSelect SuRe column. The protein was eluted in one step with elution buffer. The target sample was isolated and the buffer was exchanged into PBS. As a result, fusion proteins of anti-TIGIT antibody and TGF-βR, TF01 and TF02, were prepared.
[0119] Example 5: ELISA analysis of the binding activity of TF01 and TF02 to antigen or TGF-β 1. Indirect ELISA analysis of the binding activity of TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) to the antigen TIGIT-mFc
[0120] The method is as follows. A microplate was coated with 2 μg / mL goat anti-mouse IgG Fc (Jackson, Cat. No. 115-005-071) and incubated overnight at 4°C. The microplate was then washed once with PBST and blocked for 2 hours at 37°C using a PBS solution containing 1% BSA as a blocking solution. After blocking, the microplate was washed three times with PBST. Then, 1 μg / mL TIGIT-mFc was added, the microplate was incubated for 30 minutes at 37°C, and then washed three times with PBST. Antibodies serially diluted in PBST solution (antibody dilution gradient is shown in Table 3) were added. The microplate containing the test antibodies was incubated for 30 minutes at 37°C, and then washed three times with PBST. After washing, a secondary antibody working solution of HRP-conjugated goat anti-human IgG (H+L) (Jackson, Cat. No. 109-035-098) diluted 1:5000 was added, and the microplate was then incubated at 37°C for 30 min. After incubation, the plate was washed 4 times with PBST. TMB (Neogen, 308177) was then added in the dark to develop the color for 5 min, and the color reaction was stopped by adding stop solution. The microplate was immediately placed in a microplate reader, and the OD value of each well in the microplate was read at 450 nm. Data analysis and processing were performed with SoftMax Pro 6.2.1.
[0121] The results are shown in Table 3 and FIG. [Table 4]
[0122] From the figure, it can be seen that TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) could effectively bind to the antigen TIGIT-mFc in a dose-dependent manner. EC 50 The values are shown in Table 3. Based on the quantitative analysis of the absorbance of the bound antibodies, the results obtained by curve fitting showed that the binding efficiency EC 50The values were 0.067 nM, 0.091 nM, 0.046 nM, and 0.055 nM, respectively.
[0123] The above experimental results show that TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) had the activity of effectively binding to TIGIT-mFc.
[0124] 2. Indirect ELISA analysis of the binding activity of TF01, TF02, and TGF-βRII-mFc to TGF-β1, TGF-β2, and TGF-β3
[0125] The method is as follows. Three microplates were coated with TGF-β1, TGF-β2, and TGF-β3 at 1 μg / mL, 2 μg / mL, and 1 μg / mL, respectively, and incubated overnight at 4°C. The antigen-coated microplates were then washed once with PBST and blocked for 2 hours at 37°C using PBS solution containing 1% BSA as a blocking solution. After blocking, the microplates were washed three times with PBST. Then, antibodies serially diluted in PBST solution and TGF-βRII-mFc were added. The microplates containing the test antibodies and TGF-βRII-mFc were incubated for 30 minutes at 37°C, and then washed three times with PBST. After washing, secondary antibody working solutions of HRP-labeled goat anti-human IgG (H+L) (Jackson, Catalog No. 109-035-098) and HRP-labeled goat anti-mouse IgG Fc (Jackson, Catalog No. 115-035-071) diluted at a ratio of 1:5000 were added, and the microplate was then incubated at 37°C for 30 minutes. After incubation, the plate was washed 4 times with PBST. TMB (Neogen, 308177) was then added in the dark to develop the color for 5 minutes, and the color reaction was stopped by adding stop solution. The microplate was immediately placed in a microplate reader, and the OD value of each well in the microplate was read at 450 nm. Data analysis and processing were performed with SoftMax Pro 6.2.1.
[0126] The results are shown in Tables 4, 5, and 6 and in Figures 2, 3, and 4. [Table 5] [Table 6] [Table 7]
[0127] Based on the quantitative analysis of the absorbance of the bound antibody, the results obtained by curve fitting showed that the binding efficiency of TF01 to TGF-β1, TGF-β2, and TGF-β3, EC 50 The values were 0.207 nM, 0.477 nM, and 0.215 nM, respectively, and the binding efficiencies EC 50 The values were 0.224 nM, 0.594 nM, and 0.234 nM, respectively, and the binding efficiencies EC 50 The values were 0.356 nM, 1.029 nM, and 0.402 nM, respectively.
[0128] The results show that TF01 and TF02 have effective binding activity to TGF-β1, TGF-β2, and TGF-β3 in a dose-dependent manner. The results further show that TF01, TF02, and TGF-βRII-mFc can effectively bind to TGF-β1, TGF-β2, and TGF-β3, respectively, and that TF01 and TF02 have higher binding ability to TGF-β1, TGF-β2, and TGF-β3 than TGF-βRII-mFc.
[0129] Example 6: ELISA analysis of the activity of TF01 and TF02 to compete with TGF-βRII-His-biotin for binding to human TGF-β1 and TGF-β3 Experimental steps: Two microplates were coated with 2 μg / mL TGF-β1 and TGF-β3, respectively, and incubated overnight at 4°C. After incubation, the antigen-coated microplate was rinsed once with PBST and blocked for 2 hours using PBS solution containing 1% BSA as a blocking solution. After blocking, the microplate was washed three times with PBST. Antibodies serially diluted with PBST solution and TGF-βRII-mFc were added to the microplate. For the TGF-β1 microplate, after incubation at room temperature for 60 minutes, the plate was washed three times with PBST, and then 0.01 μg / mL TGF-βRII-His-biotin was added and incubated at room temperature for 10 minutes. For the TGF-β3 microplate, after incubation at 37°C for 30 minutes, the plate was washed three times with PBST, and then 0.01 μg / mL TGF-βRII-His-biotin was added and incubated at 37°C for 30 minutes. After incubation, the plate was washed three times with PBST. After washing, SA-HRP working solution diluted 1:4000 was added and the microplate was incubated at 37°C for 30 min. After incubation, the plate was washed four times with PBST. TMB (Neogen, 308177) was then added in the dark to develop color for 4 min, and the color reaction was stopped by adding stop solution. The microplate was immediately placed in a microplate reader, and the OD value of each well in the microplate was read at 450 nm. Data were analyzed and processed using SoftMax Pro 6.2.1.
[0130] The results for antibodies competing with TGF-βRII-His-biotin for binding to TGF-β1 and TGF-β3 are shown in Tables 7 and 8 and Figures 5 and 6. Curves of absorbance vs. antibody concentration were fitted to obtain the EC 50 The values were calculated and the results are shown in Tables 7 and 8 below. [Table 8] [Table 9]
[0131] Based on the quantitative analysis of the absorbance of the bound antibodies, the results obtained by curve fitting gave the binding efficiency EC of TF01, TF02, and TGF-βRII-mFc, which compete with TGF-βRII-His-biotin for binding to TGF-β1. 50 The values were 5.579 nM, 7.469 nM, and 6.475 nM, respectively, which are the binding efficiencies EC of TF01, TF02, and TGF-βRII-mFc that compete with TGF-βRII-His-biotin for binding to TGF-β3. 50 The values were 3.569 nM, 3.879 nM, and 2.808 nM, respectively.
[0132] The results show that TF01 and TF02 can effectively bind to TGF-β1 and TGF-β3 in a dose-dependent manner. TF01 also has a higher binding ability to TGF-β1 than TGF-βRII-His-biotin. TF01 also has a higher ability to compete with TGF-βRII-His-biotin for binding to TGF-β1 than TGF-βRII-mFc.
[0133] Example 7: ELISA analysis of the activity of TF01 and TF02 to compete with CD155-hFc-biotin for binding to human TIGIT-mFc A microplate was coated with 2 μg / mL human TIGIT-mFc (TIGIT GenBank ID: NP-776160.2) and incubated overnight at 4°C. After incubation, the microplate was blocked with PBS solution containing 1% BSA at 37°C for 2 hours. After blocking, the plate was washed three times and dried. The antibody was serially diluted to seven concentrations at a gradient ratio of 1:3 on a dilution plate, starting at 20.18 nM (final concentration 10.09 nM), and a blank control was also set. Then, an equal amount of human CD155-hFc-biotin solution at 4 μg / mL (final concentration 2 μg / mL) was added and the system was mixed well. The mixture was then incubated at room temperature for 20 minutes. The reaction mixture was then added to the coated microplate, and the microplate was incubated at 37°C for 30 minutes. After incubation, the plate was washed three times with PBST and dried. SA-HRP (KPL, 14-30-00) working solution was added and the plate was incubated at 37°C for 30 minutes. After incubation, the plate was washed four times and dried. TMB (Neogen, 308177) was then added in the dark to develop color for 5 minutes, and the color reaction was stopped by adding stop solution. The microplate was immediately placed in a microplate reader, and the OD value of each well in the microplate was read at 450 nm. Data analysis and processing were performed with SoftMax Pro 6.2.1.
[0134] The results are shown in Figure 7. The OD values for all doses are shown in Table 9. Based on the quantitative analysis of the absorbance intensity of the bound antibody, the antibody binding efficiency EC 50 The values were obtained (Table 9). [Table 10]
[0135] EC of TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) (control) to block TIGIT-mFc binding to its ligand CD155-hFc-biotin 50The values were 1.463 nM, 1.963 nM, 1.423 nM, and 1.675 nM, respectively.
[0136] The results show that TF01, TF02, 26B12H2L2 (hG4DM), and RG6058 (hG4) (control) can effectively block the binding of the antigen human CD155-hFc-biotin to its receptor human TIGIT-mFc in a dose-dependent manner. TF01 was more potent at blocking the binding of TIGIT-mFc to its ligand CD155-hFc-biotin than the control antibody RG6058 (hG4).
[0137] Example 8: FACS analysis of the binding activity of TFO1 to TIGIT on the surface of 293T-TIGIT membrane Harvest 293T-TIGIT cells in logarithmic growth phase and plate 3 x 10 cells in a clear V-bottom 96-well plate. 5 Cells / well were transferred. 1% PBSA at 350g was added, the mixture was centrifuged for 5 minutes, and the supernatant was removed. 100 μL of antibodies diluted in 1% PBSA (final concentrations of 100 nM, 33.33 nM, 11.11 nM, 3.7 nM, 1.23 nM, 0.41 nM, 0.041 nM, 0.0041 nM, and 0.00041 nM, respectively) were added. The system was gently mixed uniformly, and the mixture was incubated on ice for 1 hour. Then, 1% PBSA at 350g was added, the mixture was centrifuged for 5 minutes, and the supernatant was removed. FITC-labeled goat anti-human IgG secondary antibody (Jackson, catalog number 109-095-098) diluted 350 times was added, resuspended and mixed uniformly, and the mixture was incubated on ice in the dark for 0.5 hours. 1% PBSA was added at 350 g, the mixture was centrifuged for 5 min, the supernatant was removed, and 400 μL of PBSA was added to resuspend the cell pellet, and the resulting mixture was transferred to a flow tube for FACS Calibur analysis.
[0138] The experimental results are shown in Table 10 and Figure 8. Both TF01 and RG6058 (hG4) (control antibody) were able to specifically bind to TIGIT on the surface of the 293T-TIGIT membrane. [Table 11]
[0139] EC of TF01 and RG6058 (hG4) binding to 293T-TIGIT cells 50 The values were 1.540 nM and 1.612 nM, respectively, under the same experimental conditions.
[0140] The results showed that TF01 had effective binding activity to TIGIT on the surface of 293T-TIGIT membrane in a dose-dependent manner, and had a higher binding ability than the control antibody RG6058 (hG4).
[0141] Example 9: Analysis by competitive flow cytometry of TF01 competing with CD155 or CD112 for binding to the antigen TIGIT on the cell membrane surface 293T-TIGIT cells were conventionally digested and divided into several samples so that each well had 300,000 cells, followed by centrifugation and washing. Then, 100 μL of the corresponding gradient diluted antibody was added to each well, and the mixture was incubated on ice for 30 minutes. Then, 100 μL of CD155 / CD112-mFc (prepared by Akeso Biopharma; Lot No. 20190726 / 20190726) was added to each well, and the system was mixed well to a final concentration of 10 nM / 30 nM. Then, the mixture was incubated on ice for 1 hour. Then, 1% PBSA at 350 g was added, the mixture was centrifuged for 5 minutes, and the supernatant was removed. 100 μL of APC goat anti-mouse IgG antibody (Biolegend, Cat. No. 405308) diluted at a ratio of 1:300 was added to each well, and 100 μL of 1% PBSA was added to the blank sample, and the system was mixed well. The mixture was then incubated on ice in the dark for 30 minutes, then centrifuged, washed, and resuspended before being transferred to flow cytometry tubes for testing.
[0142] The results are shown in Figures 9 and 10. 50The values are shown in Table 11. Fluorometric analysis and curve fitting revealed that EC50 of TF01 competed for binding to the antigen. 50 The values were calculated to be 1.2720 nM and 0.7445 nM, respectively. [Table 12]
[0143] The results show that TF01 antibody can effectively block the binding of CD155 and / or CD112 to TIGIT on the surface of 293T-TIGIT host cells in a dose-dependent manner.
[0144] Example 10: Analysis of the affinity of TF01 for the Fc receptor FcγRI The Fc receptor FcγRI (also known as CD64) can bind to the Fc fragment of IgG antibodies and is involved in antibody-dependent cell-mediated cytotoxicity (ADCC). The binding ability of therapeutic antibodies to Fc receptors may affect the safety and efficacy of the antibodies. In the experiment, the affinity constant of TF01 for FcγRI was measured using the Fortebio Octet system to evaluate the ADCC activity of the antibody.
[0145] The method for measuring the affinity constant of the corresponding antibody to FcγRI by Fortebio Octet system is briefly described below. The sample dilution buffer was 0.02% Tween-20 and 0.1% BSA in PBS (pH 7.4). 1 μg / mL FcγRI solution (purchased from Sinobio) was added to the HIS1K sensor, and FcγRI was immobilized on the sensor surface for 50 seconds. Both the binding and dissociation constants of the antibody to FcγRI were measured in buffer with antibody concentrations from 3.12 to 50 nM (2-fold serial dilution). The shaking speed of the sample plate was 1000 rpm, the temperature was 30°C, and the frequency was 5.0 Hz. The affinity constants were obtained by fitting and analyzing the data with a 1:1 model.
[0146] The results regarding the affinity constant of FcγRI for TF01 are shown in Table 12 and Figures 11 to 12. [Table 13] N / A indicates that either the antibody did not bind or the signal for the antigen was so weak that analysis of the results was not performed and no corresponding data was obtained.
[0147] The results show that 26B12H2L2 (hG1WT) could bind to FcγRI with an affinity constant of 6.51E-09M, and for TF01, it did not bind to FcγRI or the binding signal was extremely weak, so the results were not analyzed and no corresponding data was obtained.
[0148] The results show that the binding activity of TF01 to FcγRI was effectively eliminated.
[0149] Example 11: Analysis of the affinity of TF01 for the Fc receptor FcγRIIIa and its subtypes (1) Analysis of the affinity constant of FcγRIIIa_V158 for TF01 The Fc receptor FcγRIIIa_V158 (also known as CD16a_V158) can bind to the Fc fragment of IgG antibodies and mediate the ADCC effect. In the experiment, the affinity constant of TF01 for FcγRIIIa_V158 was measured using the Fortebio Octet system to evaluate the ADCC activity of the antibody.
[0150] The method for measuring the affinity constant of the corresponding antibody by the Fortebio Octet system is briefly described below. The sample dilution buffer was 0.02% Tween-20 and 0.1% BSA in PBS (pH 7.4). 5 μg / mL of FcγRIIIa_V158 was immobilized on the HIS1K sensor for 60 seconds. The sensor was equilibrated in the buffer for 60 seconds, and the binding of the immobilized FcγRIIIa_V158 on the sensor to the antibody at a concentration of 31.25-500 nM (2-fold serial dilution) was measured for 60 seconds. The antibody was dissociated in the buffer for 60 seconds. The shaking speed of the sample plate was 1000 rpm, the temperature was 30 °C, and the frequency was 5.0 Hz. The affinity constant was obtained by fitting and analyzing the data with a 1:1 model.
[0151] The results regarding the affinity constant of FcγRIIIa_V158 for TF01 are shown in Table 13 and Figures 13 to 14. [Table 14] N / A indicates that either the antibody did not bind or the signal for the antigen was so weak that analysis of the results was not performed and no corresponding data was obtained.
[0152] The results show that 26B12H2L2 (hG1WT) could bind to FcγRIIIa_V158 with an affinity constant of 5.54E-08M, and that for TF01, it did not bind to FcγRIIIa_V158 or the binding signal was extremely weak, so the results were not analyzed and no corresponding data was obtained.
[0153] The results show that the binding activity of TF01 to FcγRIIIa_V158 was effectively eliminated.
[0154] (2) Analysis of the affinity constant of FcγRIIIa_F158 for TF01 The Fc receptor FcγRIIIa_F158 (also known as CD16a_F158) can bind to the Fc fragment of IgG antibodies and mediate the ADCC effect. In the experiment, the affinity constant of TF01 for FcγRIIIa_F158 was measured using the Fortebio Octet system to evaluate the ADCC activity of the antibody.
[0155] The method for measuring the affinity constant of TF01 for FcγRIIIa_F158 by the Fortebio Octet system is briefly described below. The sample dilution buffer was 0.02% Tween-20 and 0.1% BSA in PBS (pH 7.4). 5 μg / mL of FcγRIIIa_V158 was immobilized on the HIS1K sensor for 120 seconds. The sensor was equilibrated in the buffer for 60 seconds, and the binding of the immobilized FcγRIIIa_V158 on the sensor to antibodies at concentrations of 31.25-500 nM (2-fold serial dilution) was measured for 60 seconds. The antibody was dissociated in the buffer for 60 seconds. The shaking speed of the sample plate was 1000 rpm, the temperature was 30° C., and the frequency was 5.0 Hz. The affinity constant was obtained by fitting and analyzing the data with a 1:1 model.
[0156] The results regarding the affinity constant of FcγRIIIa_F158 for TF01 are shown in Table 14 and Figures 15 to 16. [Table 15] N / A indicates that either the antibody did not bind or the signal for the antigen was so weak that analysis of the results was not performed and no corresponding data was obtained.
[0157] The results show that 26B12H2L2 (hG1WT) was able to bind to FcFcγRIIIa_F158 with an affinity constant of 9.97E-08M, and that for TF01, it did not bind to FcFcγRIIIa_F158 or the binding signal was extremely weak, so the results were not analyzed and no corresponding data was obtained.
[0158] The results show that the binding activity of TF01 to FcγRIIIa_F158 was effectively eliminated.
[0159] Example 12: Analysis of the affinity of TF01 for the Fc receptor FcγRIIa and its subtypes (1) Analysis of the affinity constant of FcγRIIa_H131 for TF01 The Fc receptor FcγRIIa_H131 (also known as CD32a_H131) can bind to the Fc fragment of IgG antibodies and is involved in antibody-dependent cell-mediated cytotoxicity (ADCC). The binding ability of therapeutic antibodies to Fc receptors is likely to affect the safety and efficacy of the antibodies. In the experiment, the affinity constant of TF01 for FcγRIIa_H131 was measured using a Fortebio Octet system to evaluate the binding ability of the test antibodies to the Fc receptor.
[0160] The method for measuring the affinity constant of TF01 for FcγRIIa_H131 by the Fortebio Octet system is briefly described below. The sample dilution buffer was 0.02% Tween-20 and 0.1% BSA in PBS (pH 7.4). 5 μg / mL of FcγRIIa_H131 was immobilized on the NTA sensor at an immobilization height of about 1.0 nm. The sensor was equilibrated in the buffer for 60 seconds, and the binding of the immobilized FcγRIIa_H131 on the sensor to antibodies at concentrations of 12.5 to 200 nM (2-fold serial dilution) was measured for 60 seconds. The antibody was dissociated in the buffer for 60 seconds. The shaking speed of the sample plate was 1000 rpm, the temperature was 30 °C, and the frequency was 5.0 Hz. The affinity constant was obtained by fitting and analyzing the data with a 1:1 model.
[0161] The results regarding the affinity constant of FcγRIIa_H131 for TF01 are shown in Table 15 and Figures 17 to 18. [Table 16] N / A indicates that either the antibody did not bind or the signal for the antigen was so weak that analysis of the results was not performed and no corresponding data was obtained.
[0162] The results show that 26B12H2L2 (hG1WT) could bind to FcγRIIa_H131 with an affinity constant of 3.90E-08M, and for TF01, it did not bind to FcγRIIa_H131 or the binding signal was extremely weak, so the results were not analyzed and no corresponding data was obtained.
[0163] The results show that the binding activity of TF01 to FcγRIIa_H131 was effectively eliminated.
[0164] (2) Analysis of the affinity constant of FcγRIIa_R131 for TF01 The Fc receptor FcγRIIa_R131 (also known as CD32a_R131) can bind to the Fc fragment of IgG antibodies and is involved in antibody-dependent cell-mediated cytotoxicity (ADCC). The binding ability of therapeutic antibodies to Fc receptors may affect the safety and efficacy of the antibodies. In the experiment, the affinity constant of TF01 for FcγRIIa_R131 was measured using the Fortebio Octet system to evaluate the binding ability of the test antibodies to the Fc receptor.
[0165] The method for measuring the affinity constant of TF01 for FcγRIIa_R131 by the Fortebio Octet system is briefly described below. The sample dilution buffer was 0.02% Tween-20 and 0.1% BSA in PBS (pH 7.4). 5 μg / mL of FcγRIIa_R131 was immobilized on the NTA sensor at an immobilization height of about 1.0 nm. The sensor was equilibrated in the buffer for 60 seconds, and the binding of the immobilized FcγRIIa_R131 on the sensor to antibodies at concentrations of 12.5 to 200 nM (2-fold serial dilution) was measured for 60 seconds. The antibodies were dissociated in the buffer for 60 seconds. The shaking speed of the sample plate was 1000 rpm, the temperature was 30° C., and the frequency was 5.0 Hz. The affinity constant was obtained by fitting and analyzing the data with a 1:1 model.
[0166] The results regarding the affinity constant of FcγRIIa_R131 for TF01 are shown in Table 16 and Figures 19 to 20. [Table 17] N / A indicates that either the antibody did not bind or the signal for the antigen was so weak that analysis of the results was not performed and no corresponding data was obtained.
[0167] The results show that 26B12H2L2 (hG1WT) could bind to FcγRIIa_H131 with an affinity constant of 3.22E-08M, and for TF01, it did not bind to FcγRIIa_R131 or the binding signal was extremely weak, so the results were not analyzed and no corresponding data was obtained.
[0168] The results show that the binding activity of TF01 to FcγRIIa_R131 was effectively eliminated.
[0169] Example 13: Analysis of affinity constants of FcγRIIb for TF01 The Fc receptor FcγRIIb (also known as CD32b) can bind to the Fc fragment of IgG antibodies. In the experiment, the affinity constant of the test antibody to FcγRIIb was measured using the Fortebio Octet system to evaluate the binding ability of TF01 to the Fc receptor.
[0170] The method for measuring the affinity constant of TF01 for FcγRIIb by the Fortebio Octet system is briefly described below. The sample dilution buffer was 0.02% Tween-20 and 0.1% BSA in PBS (pH 7.4). 5 μg / mL of FcγRIIb was immobilized on the NTA sensor at an immobilization height of approximately 1.0 nm. The sensor was equilibrated in the buffer for 60 seconds, and the binding of immobilized hFCGR2B-his on the sensor to antibodies at concentrations of 12.5-200 nM (2-fold serial dilution) was measured for 60 seconds. The antibodies were dissociated in the buffer for 60 seconds. The shaking speed of the sample plate was 1000 rpm, the temperature was 30°C, and the frequency was 5.0 Hz. The affinity constant was obtained by fitting and analyzing the data with a 1:1 model.
[0171] The results regarding the affinity constant of FcγRIIb for TF01 are shown in Table 17 and Figures 21 to 22. [Table 18] N / A indicates that either the antibody did not bind or the signal for the antigen was so weak that analysis of the results was not performed and no corresponding data was obtained.
[0172] The results show that 26B12H2L2 (hG1WT) could bind to FcγRIIb with an affinity constant of 4.12E-08M, and for TF01, it did not bind to FcγRIIb or the binding signal was extremely weak, so the results were not analyzed and no corresponding data was obtained.
[0173] The results show that the binding activity of TF01 to FcγRIIb was effectively eliminated.
[0174] Example 14: Analysis of the affinity of TF01 for C1q Serum complement C1q can bind to the Fc fragment of IgG antibodies and mediate the CDC effect. The binding ability of therapeutic antibodies to C1q may affect the safety and efficacy of the antibodies. In the experiment, the affinity constant of TF01 for C1q was measured using the Fortebio Octet system to evaluate the CDC activity of the antibodies.
[0175] The method for measuring the affinity constant of an antibody to C1q by the Fortebio Octet system is briefly described below. The sample dilution buffer was 0.02% Tween-20 and 0.1% BSA in PBS (pH 7.4). 50 μg / mL of antibody was immobilized on the FAB2G sensor at an immobilization height of about 2.0 nm. The sensor was equilibrated in the buffer for 60 seconds, and the binding of the immobilized antibody on the sensor to the antigen C1q at concentrations of 0.625 to 10 nM (2-fold serial dilution) was measured for 60 seconds. The antigen-antibody was dissociated in the buffer for 60 seconds. The shaking speed of the sample plate was 1000 rpm, the temperature was 30°C, and the frequency was 5.0 Hz. The affinity constant was obtained by fitting and analyzing the data with a 1:1 model. The data acquisition software was Fortebio Data Acquisition 7.0, and the data analysis software was Fortebio Data Analysis 7.0.
[0176] The results regarding the affinity constant of TF01 for C1q are shown in Table 18 and Figures 23-24. [Table 19] N / A indicates that either the antibody did not bind or the signal for the antigen was so weak that analysis of the results was not performed and no corresponding data was obtained.
[0177] The results show that 26B12H2L2 (hG1WT) could bind to C1q with an affinity constant of 1.28E-09M, and for TF01, it did not bind to C1q or the binding signal was extremely weak, so the results were not analyzed and no corresponding data was obtained.
[0178] The results show that the binding activity of TF01 to C1q was effectively abolished.
[0179] Example 15: Antibody-dependent cellular phagocytosis activity of TF01 against CHO-K1-TIGIT To detect antibody-dependent cellular phagocytosis (ADCP) activity, mouse macrophages were used as effector cells and a TIGIT-overexpressing cell line was used as target cells to test the cell-mediated ADCP effect.
[0180] Cryopreserved mouse bone marrow-derived macrophages (MBMM) (derived from C57 mice) were removed, DMEM + 10% FBS + 100ng / mL M-CSF (macrophage colony-stimulating factor, PeproTech, Cat. No. 315-02) was added, and the mixture was centrifuged at 1200×g for 5 minutes. The cells were collected, DMEM + 10% FBS + 100ng / mL M-CSF medium was added, and the cells were thawed overnight.
[0181] Target cells (CHO-K1-TIGIT) were harvested, centrifuged at 170×g for 5 min, and washed once with PBS. Trypan blue was added for counting. 5(6)-Carboxyfluorescein N-succinimidyl ester (CFSE, Biolegend, Cat. No. 423801) was diluted to 2.5 μM in PBS and the cells were resuspended (staining density: 10,000,000 cells / mL). An appropriate amount of cells was incubated for 20 min in a cell incubator. Staining was stopped by adding 6 mL of DMEM complete medium (containing 10% FBS). The mixture was centrifuged at 170×g for 5 min, and the supernatant was removed. 1 mL of DMEM complete medium was added, and the cells were incubated for 10 min in an incubator. Antibodies were diluted to the desired concentration in DMEM complete medium, and isotype control antibodies were designed. Target cells (150,000 cells / well) were added to a 96-well V-bottom plate, followed by antibody (100 μL) and mixing the system well. The mixture was incubated on ice for 40 min, centrifuged at 170×g for 5 min, and washed twice. Macrophages (MBMM) were harvested, centrifuged at 750×g for 5 min, and the supernatant was removed. The cells were counted and resuspended in DMEM complete medium to adjust the macrophage concentration (50,000 cells / 100 μL). The cells were then added to the 96-well V-bottom plate containing the target cells, resuspended, and mixed. The mixture was incubated for 2 h at 37° C. in an incubator. 100 μL of 1% PBSA at room temperature was added to each well. The mixture was centrifuged at 750×g for 5 min, and the supernatant was removed. The cells were washed once with 200 μL of PBSA. APC anti-mouse / human CD11b antibody (Biolegend, Cat. No. 101212) (diluted 1:500 in PBSA) was added to the corresponding samples at 100 μL / well, and the system was mixed well. The mixture was then incubated on ice for 40 minutes. 100 μL of 1% PBSA was added to each well. The mixture was centrifuged at 750×g for 5 minutes, and the supernatant was removed. The cells were washed once with 200 μL of PBSA per well. The cells were resuspended in 200 μL of 1% PBSA per well and tested. Macrophages in the system were APC positive, and macrophages involved in phagocytosis were APC and CFSE double positive.The phagocytosis rate was determined as the ratio of the number of double positive cells to the number of APC positive cells, and the ADCP activity was evaluated accordingly. The ADCP activity of each group was expressed as P% and calculated by the following formula:
number
[0182] The results are shown in Figure 25.
[0183] The results showed that RG6058 (hG1WT), RG6058 (hG4), and 26B12H2L2 (hG1WT) had ADCP effects at the same concentrations, and that the phagocytosis rate of TF01 was similar to that of the isotype control antibody group at the same concentrations, indicating that TF01 does not have ADCP effect.
[0184] The results show that the amino acid mutations introduced by TF01 could effectively eliminate the ADCP effect.
[0185] Example 16: Evaluation of blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on CD112 / CD155 inhibition of IL-2 secretion in a co-culture system 1. Evaluation of blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on CD112 inhibition of IL-2 secretion in Jurkat-TIGIT and THP-1 cell co-culture systems A 96-well plate (Corning, model no. 3599) was coated with 2 μg / mL anti-human CD3 antibody (prepared by Akeso Biopharma; lot no. 20170830) for 2 hours at 37°C. Afterwards, the coating solution was removed and the plate was washed once with pre-chilled PBS (300 μL). Jurkat-TIGIT cells (constructed by Akeso Biopharma) were counted and added to the 96-well plate at 50,000 cells / well. Antibodies were added according to the experimental design and the plate was incubated at 37°C for 30 minutes. CD112-hFc (prepared by Akeso Biopharma; lot no. 20180209) was added according to the experimental design. THP-1 cells (purchased from Chinese Academy of Sciences, Catalog No. 3131C0001000700057) were counted and added to a 96-well plate at 50,000 cells / well. The plate was incubated in an incubator for 48 hours. The culture supernatant was collected and tested for IL-2 content using an IL-2 ELISA kit (Dakewe, Catalog No. 1110202).
[0186] The results are shown in Figure 26. The results show that CD112 has a significant inhibitory effect on IL-2 secretion. Antibodies 26B12H2L2 (hG4DM), TF01, TF02, RG6058 (hG1DM), and RG6058 (hG4) can effectively block CD112 inhibition on IL-2 secretion in the system, and TF01 and TF02 have stronger activity than the positive control antibodies RG6058 (hG1DM) and RG6058 (hG4).
[0187] 2. Evaluation of blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on CD155 inhibition of IL-2 secretion in Jurkat-TIGIT and THP-1 cell co-culture systems A 96-well plate (Corning, model no. 3599) was coated with 2 μg / mL anti-human CD3 antibody (prepared by Akeso Biopharma; lot no. 20170830) for 2 hours at 37°C. Afterwards, the coating solution was removed and the plate was washed once with pre-chilled PBS (300 μL). Jurkat-TIGIT cells (constructed by Akeso Biopharma) were counted and added to the 96-well plate at 50,000 cells / well. Antibodies were added according to the experimental design and the plate was incubated at 37°C for 30 minutes. CD155-hFc (prepared by Akeso Biopharma; lot no. 20180209) was added according to the experimental design. THP-1 cells (purchased from Chinese Academy of Sciences, Catalog No. 3131C0001000700057) were counted and added to a 96-well plate at 50,000 cells / well. The plate was incubated in an incubator for 48 hours. The culture supernatant was collected and tested for IL-2 content using an IL-2 ELISA kit (Dakewe, Catalog No. 1110202).
[0188] The results are shown in Figure 27. The results show that CD155 has a significant inhibitory effect on IL-2 secretion. Antibodies TF01 and RG6058 (hG1DM) can effectively block CD155 inhibition on IL-2 secretion in the system and have similar activity.
[0189] Example 17: Evaluation of the biological activity of anti-TIGIT antibody and TGF-βR fusion protein in promoting IL-2 secretion in a Jurkat-TIGIT and HT1080-aCD3scFv cell co-culture system Jurkat-TIGIT and HT1080-aCD3scFv cells (constructed by Akeso Biopharma) in logarithmic growth phase were harvested and counted, with 50,000 Jurkat-TIGIT cells per well and 10,000 HT1080-aCD3scFv cells per well. Diluted antibodies (antibody gradient: 3 nM, 30 nM, 300 nM) were added. Soluble anti-human CD28 antibody (3 μg / mL) (R&D, Cat. No. MAB342-500) was added. The mixture was incubated in an incubator for 48 hours. Culture supernatants were collected and tested for IL-2 content using an IL-2 ELISA kit (Dakewe, Cat. No. 1110202).
[0190] The results are shown in Figure 28.
[0191] The results show that antibodies TF01, TF02, and RG6058 (hG4) can effectively promote IL-2 secretion in Jurkat-TIGIT and HT1080-scFv cell co-culture systems, and have comparable activities.
[0192] Example 18: Evaluation of the blocking activity of anti-TIGIT antibody and TGF-βR fusion protein on TGF-β1 inhibition of IFN-γ secretion during PBMC secondary immune response to CMV antigen PBMCs (from healthy donors) were thawed and seeded on complete medium (RPMI1640+10% FBS) and incubated overnight in an incubator. The next day, cells were harvested and counted to determine cell viability, and seeded at 200,000 cells / well on round-bottom 96-well plates (Corning, Cat. No. 3799). Meanwhile, gradient diluted antibodies, CMV (final concentration 0.02 μg / mL, Mabtech, Cat. No. 3619-1), and TGF-β1 (final concentration 3 ng / mL, Genscript, Cat. No. Z03411) were added according to the experimental design to a final volume of 200 μL. (TGF-β1 and antibodies were incubated for 10 min at 37°C.) The mixture was incubated in an incubator for 4 days. After 4 days, cell culture supernatants were harvested and tested for IFN-γ content using an IFN-γ ELISA kit (Dakewe, Cat. No. 1110002).
[0193] The results are shown in Figure 29. The results show that CMV antigen can induce the secretion of IFN-γ by PBMC secondary immune response, and TGF-β1 has a significant inhibitory effect on IFN-γ secretion in the system. The combination of antibody TF01, anti-HEL&TGFβ, and anti-HEL&TGFβ+26B12H2L2(hG1DM) can effectively block TGF-β1 inhibition on IFN-γ secretion in the system, which was not achieved by using 26B12H2L2(hG1DM) alone. The blocking activity of TF01 was superior to that of the control antibody anti-HEL&TGFβ and was comparable to that of anti-HEL&TGFβ+26B12H2L2(hG1DM).
[0194] Example 19: Pharmacodynamic evaluation of anti-TIGIT antibody and TGF-βR fusion protein in a mouse tumor cell subcutaneous xenograft model To measure the antitumor activity of the fusion protein of anti-TIGIT antibody and TGF-βR in vivo, MDA-MB-231 cells (purchased from ATCC) were first subcutaneously inoculated into the mammary fat pad of 6.71-9.57 week-old female Scid Beige mice (purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.). 17 days after inoculation, the mice were randomly divided into three groups of eight mice each according to tumor volume. Each mouse was intraperitoneally injected with human peripheral blood mononuclear cells (hPBMCs), and the administration was performed, and the day of grouping was defined as D0. The administration route was intraperitoneal injection, and injections were performed once a week for 6 weeks. Intraperitoneal injection of hPBMCs was performed 8 days after grouping. Modeling and specific regimens are shown in Table 19. After administration, the length and width of the tumor in each group were measured, and the tumor volume was calculated. [Table 20]
[0195] The results are shown in Figure 30. The results show that, compared with the isotype control antibody, the anti-TIGIT antibody and TGF-βR fusion protein TF01 could effectively inhibit tumor growth in mice.
[0196] Furthermore, as shown in FIG. 31, the tumor-bearing mice were highly resistant to the test drug TF01, and there was no effect on the body weight of the tumor-bearing mice in each group.
[0197] Although the specific embodiments of the present invention have been described in detail, those skilled in the art will understand that various modifications and substitutions can be made to these details according to any teaching disclosed. All such modifications are included within the protection scope of the present invention. The full scope of the present invention is provided by the appended claims and any equivalents thereof.
Claims
1. A first protein functional region that targets TIGIT; and a second protein functional domain having TGF-β binding activity; A fusion protein comprising: the first protein functional domain is an anti-TIGIT antibody or an antigen-binding fragment thereof; the heavy chain variable region of the anti-TIGIT antibody comprises HCDR1 to HCDR3 having the amino acid sequences of SEQ ID NOs: 3 to 5, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences of SEQ ID NOs: 8 to 10, respectively; Fusion proteins.
2. the heavy chain variable region of the anti-TIGIT antibody comprises an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17; the light chain variable region of the anti-TIGIT antibody comprises an amino acid sequence selected from SEQ ID NO:6, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:25; The fusion protein of claim 1.
3. 2. The fusion protein of claim 1 , the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO:1, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:6; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO:11, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:19; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 17, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 19; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 13, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 21; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 13, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 23; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 15, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 21; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 15, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 23; the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 11 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 25; or the heavy chain variable region of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO: 17, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 25; Fusion proteins.
4. The anti-TIGIT antibody or antigen-binding fragment thereof is Fab, Fab', F(ab') 2 2. The fusion protein of claim 1, selected from the group consisting of an Fd, an Fv, a dAb, a complementarity determining region fragment, a single chain antibody, a humanized antibody, a chimeric antibody, and a diabody.
5. The fusion protein of claim 1 , wherein the anti-TIGIT antibody comprises non-CDR regions derived from a species other than mouse, e.g., from a human antibody.
6. The fusion protein according to claim 1, wherein the heavy chain constant region of the anti-TIGIT antibody is an Ig gamma-1 chain C region (NCBI accession number P01857, etc.) or an Ig gamma-4 chain C region (NCBI accession number P01861.1, etc.), and the light chain constant region of the anti-TIGIT antibody is an Ig kappa chain C region (NCBI accession number P01834, etc.).
7. The fusion protein of claim 1, which has a higher binding ability to the ligand CD155-hFc-biotin than the control antibody RG6058 (hG4).
8. The fusion protein has an EC 50 and preferably said EC 50 The fusion protein of claim 1 , wherein the fusion protein is measured by indirect ELISA.
9. The fusion protein has an EC value of less than 0.3 nM, less than 0.4 nM, less than 0.5 nM, or less than 0.6 nM for TGF-β1, TGF-β2, or TGF-β3. 50 and preferably said EC 50 The fusion protein of claim 1, wherein is measured by indirect ELISA.
10. The fusion protein of claim 1, wherein the anti-TIGIT antibody is an antibody produced by hybridoma cell line LT019 deposited at the China Center for Type Culture Collection (CCTCC) under CCTCC number C2020208.
11. The fusion protein of claim 1, When the heavy chain constant region of the anti-TIGIT antibody is an IgG1 heavy chain constant region, the heavy chain constant region of the anti-TIGIT antibody may have the following combination of mutations based on the EU numbering system: L234A and L235A; L234A and G237A; L235A and G237A; or L234A, L235A, and G237A; or When the heavy chain constant region of the anti-TIGIT antibody is an IgG4 heavy chain constant region, the heavy chain constant region of the anti-TIGIT antibody may have the following combination of mutations based on the EU numbering system: F234A and L235A; F234A and G237A; L235A and G237A; or F234A, L235A, and G237A, having one of Fusion proteins.
12. the second protein functional domain is a TGF-β receptor, an extracellular domain thereof, or a truncated fragment of the extracellular domain of a TGF-β receptor having TGF-β receptor function; Preferably, the TGF-β receptor is TGF-βRI, TGF-βRII, or TGF-βRIII, or the extracellular domain of TGF-βRI, TGF-βRII, or TGF-βRIII, or a truncated fragment of the extracellular domain of TGF-βRI, TGF-βRII, or TGF-βRIII; Preferably, the second protein functional domain comprises the amino acid sequence of any one of SEQ ID NOs: 33-39; The fusion protein of claim 1.
13. The fusion protein of claim 1 , wherein the heavy chain of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO:27 or SEQ ID NO:31, and the light chain comprises the amino acid sequence of SEQ ID NO:
29.
14. The fusion protein of claim 1 , wherein the first protein functional domain and the second protein functional domain are linked directly or via a linker fragment.
15. 15. The fusion protein of claim 14, wherein the linker fragment is (GGGGS)n (SEQ ID NO: 49) or (GGGGS)nG (SEQ ID NO: 50), where n is a positive integer, preferably n is 1, 2, 3, 4, 5, or 6.
16. 2. The fusion protein of claim 1, wherein the number of the first protein functional domain and the second protein functional domain is independently one, two, or more.
17. The fusion protein of claim 12, wherein the TGF-β receptor or an extracellular fragment thereof is linked to the C-terminus of the heavy chain of the anti-TIGIT antibody.
18. A first protein functional region that targets TIGIT; and a second protein functional domain having TGF-β binding activity; A fusion protein comprising: the number of said first protein functional regions is 1 and the number of said second protein functional regions is 2; the first protein functional domain is an anti-TIGIT antibody or an antigen-binding fragment thereof, and the second protein functional domain is a TGF-β receptor, an extracellular domain thereof, or a truncated fragment of the extracellular domain of a TGF-β receptor having TGF-β receptor function; the heavy chain of the anti-TIGIT antibody comprises the amino acid sequence of SEQ ID NO:27 or SEQ ID NO:31, and the light chain comprises the amino acid sequence of SEQ ID NO:29; the second protein functional domain comprises the amino acid sequence of SEQ ID NO:33; the second protein functional region is linked to the C-terminus of the heavy chain of the anti-TIGIT antibody via a linker fragment; Preferably, the linker fragment comprises the amino acid sequence of SEQ ID NO: 44; Fusion proteins.
19. An isolated nucleic acid molecule encoding a fusion protein according to any one of claims 1 to 18.
20. A vector comprising the isolated nucleic acid molecule of claim 19.
21. 20. A host cell comprising the isolated nucleic acid molecule of claim 19.
22. A conjugate comprising a fusion protein portion and a conjugated moiety, wherein the fusion protein portion is the fusion protein according to any one of claims 1 to 18, and the conjugated moiety is a detectable label, preferably a radioisotope, a fluorescent substance, a luminescent substance, a colored substance, or an enzyme.
23. Use of a fusion protein according to any one of claims 1 to 18 in the preparation of a kit for detecting the presence or concentration of TIGIT and / or TGF-β in a sample.
24. A pharmaceutical composition comprising the fusion protein of any one of claims 1 to 18, said pharmaceutical composition optionally further comprising a pharmacologically acceptable carrier and / or excipient.
25. 25. The pharmaceutical composition according to claim 24, further comprising one or more antitumor chemotherapeutic agents, preferably the antitumor chemotherapeutic agent is a tyrosine kinase inhibitor, more preferably the antitumor chemotherapeutic agent is anlotinib or a pharmacologically acceptable salt thereof (such as the hydrochloride salt), or lenvatinib or a pharmacologically acceptable salt thereof (such as the mesylate salt).
26. 25. The pharmaceutical composition according to claim 24, wherein the unit dose of the pharmaceutical composition is 100 mg to 1500 mg, 200 mg to 1000 mg, 200 mg to 800 mg, 300 mg to 600 mg, 400 mg to 500 mg, or 450 mg based on the mass of the fusion protein.
27. A combination product comprising a first product and a second product in separate packages, The first product comprises a fusion protein according to any one of claims 1 to 18; The second product comprises one or more anti-tumor chemotherapeutic agents, preferably the anti-tumor chemotherapeutic agent is a tyrosine kinase inhibitor, more preferably the anti-tumor chemotherapeutic agent is anlotinib or a pharmacologically acceptable salt thereof (such as the hydrochloride salt), or lenvatinib or a pharmacologically acceptable salt thereof (such as the mesylate salt); Preferably, said first product and said second product independently further comprise one or more pharmacologically acceptable excipients; Preferably, the combination product further comprises a package insert; Combination products.
28. 28. The combination product of claim 27, wherein the unit dose of the first product is between 100 mg and 1500 mg, between 200 mg and 1000 mg, between 200 mg and 800 mg, between 300 mg and 600 mg, between 400 mg and 500 mg, or between 450 mg, based on the mass of the fusion protein.
29. 28. The combination product of claim 27, wherein the unit dose of the second product is from 0.1 mg to 100 mg, from 0.5 mg to 50 mg, from 1 mg to 20 mg, from 2 mg to 15 mg, from 4 mg to 12 mg, or from 8 mg to 12 mg based on the mass of active ingredient.
30. Use of a fusion protein according to any one of claims 1 to 18 in the preparation of a medicament for the treatment and / or prevention of a tumor, comprising Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B-cell lymphoma, plasmacytoma, renal cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer; use.
31. Fusion protein according to any one of claims 1 to 18 for use in the treatment and / or prevention of tumors, Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B-cell lymphoma, plasmacytoma, renal cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer; Fusion proteins.
32. A pharmaceutical composition for treating and / or preventing tumors, comprising an effective amount of a fusion protein according to any one of claims 1 to 18; Preferably, the tumor is selected from one or more of non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B-cell lymphoma, plasmacytoma, renal cell carcinoma, prostate cancer, and pancreatic ductal adenocarcinoma; Preferably, the non-small cell lung cancer is advanced non-small cell lung cancer; Pharmaceutical compositions.
